This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-128-3p | ABL1 | 0.98 | 6.0E-5 | -0.96 | 0 | MirTarget | -0.16 | 0.00096 | NA | |
2 | hsa-miR-141-3p | ABL1 | 1.46 | 0.00116 | -0.96 | 0 | MirTarget | -0.19 | 0 | NA | |
3 | hsa-miR-142-5p | ABL1 | 1.56 | 1.0E-5 | -0.96 | 0 | MirTarget | -0.17 | 0 | NA | |
4 | hsa-miR-15b-3p | ABL1 | 1.76 | 0 | -0.96 | 0 | MirTarget | -0.15 | 4.0E-5 | NA | |
5 | hsa-miR-15b-5p | ABL1 | 1.62 | 0 | -0.96 | 0 | mirMAP | -0.2 | 0 | NA | |
6 | hsa-miR-16-5p | ABL1 | 1.01 | 1.0E-5 | -0.96 | 0 | mirMAP | -0.28 | 0 | NA | |
7 | hsa-miR-19a-3p | ABL1 | 1.27 | 0.00011 | -0.96 | 0 | mirMAP | -0.16 | 2.0E-5 | NA | |
8 | hsa-miR-200a-3p | ABL1 | 0.72 | 0.19391 | -0.96 | 0 | MirTarget | -0.12 | 0 | NA | |
9 | hsa-miR-29a-5p | ABL1 | 0.59 | 0.02301 | -0.96 | 0 | MirTarget | -0.13 | 0.00827 | NA | |
10 | hsa-miR-30b-5p | ABL1 | -0.43 | 0.05936 | -0.96 | 0 | MirTarget; miRNATAP | -0.14 | 0.0083 | NA | |
11 | hsa-miR-30e-5p | ABL1 | -0.57 | 0.01125 | -0.96 | 0 | MirTarget; miRNATAP | -0.15 | 0.00794 | NA | |
12 | hsa-miR-330-5p | ABL1 | 0.49 | 0.05122 | -0.96 | 0 | MirTarget | -0.24 | 0 | NA | |
13 | hsa-miR-423-5p | ABL1 | 0.83 | 0.00079 | -0.96 | 0 | MirTarget | -0.15 | 0.00245 | NA | |
14 | hsa-miR-484 | ABL1 | 0.71 | 0.00234 | -0.96 | 0 | miRNAWalker2 validate | -0.26 | 0 | NA | |
15 | hsa-miR-503-5p | ABL1 | 1.89 | 0 | -0.96 | 0 | mirMAP | -0.1 | 0.00051 | NA | |
16 | hsa-let-7d-5p | ABL2 | 0.98 | 0 | 0.26 | 0.18922 | miRNATAP | -0.22 | 0.00166 | NA | |
17 | hsa-let-7g-3p | ABL2 | 0.65 | 0.01031 | 0.26 | 0.18922 | mirMAP | -0.19 | 0.00045 | NA | |
18 | hsa-let-7g-5p | ABL2 | 0.33 | 0.24114 | 0.26 | 0.18922 | miRNATAP | -0.15 | 0.00245 | NA | |
19 | hsa-miR-106b-5p | ABL2 | 1.71 | 0 | 0.26 | 0.18922 | MirTarget | -0.18 | 5.0E-5 | NA | |
20 | hsa-miR-107 | ABL2 | 0.9 | 5.0E-5 | 0.26 | 0.18922 | MirTarget; PITA; miRanda; miRNATAP | -0.28 | 0 | NA | |
21 | hsa-miR-126-5p | ABL2 | 0.42 | 0.07532 | 0.26 | 0.18922 | mirMAP | -0.18 | 0.00191 | NA | |
22 | hsa-miR-1266-5p | ABL2 | 0.21 | 0.74156 | 0.26 | 0.18922 | MirTarget | -0.12 | 0 | NA | |
23 | hsa-miR-128-3p | ABL2 | 0.98 | 6.0E-5 | 0.26 | 0.18922 | MirTarget | -0.19 | 0.00069 | NA | |
24 | hsa-miR-140-3p | ABL2 | -0.3 | 0.12754 | 0.26 | 0.18922 | miRNAWalker2 validate | -0.24 | 0.00119 | NA | |
25 | hsa-miR-148a-5p | ABL2 | -0.69 | 0.0793 | 0.26 | 0.18922 | miRNATAP | -0.19 | 0 | NA | |
26 | hsa-miR-15b-5p | ABL2 | 1.62 | 0 | 0.26 | 0.18922 | MirTarget; miRNATAP | -0.13 | 0.00819 | NA | |
27 | hsa-miR-16-5p | ABL2 | 1.01 | 1.0E-5 | 0.26 | 0.18922 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.2 | 0.00107 | NA | |
28 | hsa-miR-17-3p | ABL2 | 1.31 | 0 | 0.26 | 0.18922 | mirMAP | -0.22 | 2.0E-5 | NA | |
29 | hsa-miR-186-5p | ABL2 | 0.15 | 0.43471 | 0.26 | 0.18922 | MirTarget; mirMAP | -0.22 | 0.00329 | NA | |
30 | hsa-miR-188-5p | ABL2 | 1.35 | 0.00038 | 0.26 | 0.18922 | mirMAP | -0.15 | 3.0E-5 | NA | |
31 | hsa-miR-200a-5p | ABL2 | 1.5 | 0.00264 | 0.26 | 0.18922 | mirMAP | -0.12 | 0 | NA | |
32 | hsa-miR-200b-3p | ABL2 | 0.97 | 0.0595 | 0.26 | 0.18922 | MirTarget | -0.13 | 0 | NA | |
33 | hsa-miR-200b-5p | ABL2 | 0.97 | 0.05305 | 0.26 | 0.18922 | mirMAP | -0.16 | 0 | NA | |
34 | hsa-miR-200c-3p | ABL2 | 1.28 | 0.0037 | 0.26 | 0.18922 | MirTarget | -0.13 | 4.0E-5 | NA | |
35 | hsa-miR-26a-5p | ABL2 | -0.38 | 0.04425 | 0.26 | 0.18922 | MirTarget; miRNATAP | -0.31 | 3.0E-5 | NA | |
36 | hsa-miR-26b-5p | ABL2 | -0.3 | 0.16008 | 0.26 | 0.18922 | MirTarget; miRNATAP | -0.33 | 0 | NA | |
37 | hsa-miR-29a-3p | ABL2 | -0.11 | 0.61501 | 0.26 | 0.18922 | mirMAP | -0.25 | 5.0E-5 | NA | |
38 | hsa-miR-29c-3p | ABL2 | -1.62 | 0 | 0.26 | 0.18922 | mirMAP | -0.13 | 0.00169 | NA | |
39 | hsa-miR-30b-5p | ABL2 | -0.43 | 0.05936 | 0.26 | 0.18922 | mirMAP | -0.21 | 0.00063 | NA | |
40 | hsa-miR-30d-3p | ABL2 | -0.55 | 0.04337 | 0.26 | 0.18922 | mirMAP | -0.16 | 0.00253 | NA | |
41 | hsa-miR-30d-5p | ABL2 | -0.55 | 0.01401 | 0.26 | 0.18922 | mirMAP; miRNATAP | -0.23 | 0.00018 | NA | |
42 | hsa-miR-30e-3p | ABL2 | -0.91 | 1.0E-5 | 0.26 | 0.18922 | mirMAP | -0.25 | 0.00019 | NA | |
43 | hsa-miR-335-5p | ABL2 | 1.6 | 6.0E-5 | 0.26 | 0.18922 | mirMAP | -0.17 | 0 | NA | |
44 | hsa-miR-33a-3p | ABL2 | 0.35 | 0.32171 | 0.26 | 0.18922 | mirMAP | -0.15 | 0.00026 | NA | |
45 | hsa-miR-378a-3p | ABL2 | -0.19 | 0.5308 | 0.26 | 0.18922 | mirMAP | -0.21 | 0 | NA | |
46 | hsa-miR-378c | ABL2 | -1.28 | 3.0E-5 | 0.26 | 0.18922 | mirMAP | -0.25 | 0 | NA | |
47 | hsa-miR-429 | ABL2 | 1.4 | 0.009 | 0.26 | 0.18922 | MirTarget | -0.13 | 0 | NA | |
48 | hsa-miR-500a-5p | ABL2 | 0 | 0.99212 | 0.26 | 0.18922 | mirMAP | -0.11 | 0.00636 | NA | |
49 | hsa-miR-589-5p | ABL2 | 0.7 | 0.00396 | 0.26 | 0.18922 | MirTarget; miRNATAP | -0.15 | 0.00782 | NA | |
50 | hsa-miR-590-3p | ABL2 | 1.12 | 0.00016 | 0.26 | 0.18922 | PITA; mirMAP; miRNATAP | -0.13 | 0.00684 | NA | |
51 | hsa-miR-625-3p | ABL2 | -0.19 | 0.62622 | 0.26 | 0.18922 | mirMAP | -0.18 | 0 | NA | |
52 | hsa-miR-7-1-3p | ABL2 | 0.71 | 0.04123 | 0.26 | 0.18922 | mirMAP | -0.14 | 0.00033 | NA | |
53 | hsa-miR-21-5p | AKT2 | 1.75 | 0 | -0.01 | 0.9227 | miRNAWalker2 validate | -0.15 | 0.00352 | NA | |
54 | hsa-miR-29b-3p | AKT2 | -0.23 | 0.36746 | -0.01 | 0.9227 | MirTarget | -0.14 | 0.00022 | 26512921; 26564501; 24076586 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3;The expression of miR-29b was significantly upregualted by cisplatin treatmentwhile its target gene AKT2 was downregulated;Furthermore a feed-back loop comprising of c-Myc miR-29 family and Akt2 were found in myeloid leukemogenesis |
55 | hsa-miR-106b-5p | AKT3 | 1.71 | 0 | -0.75 | 0.06936 | miRNATAP | -0.37 | 7.0E-5 | NA | |
56 | hsa-miR-107 | AKT3 | 0.9 | 5.0E-5 | -0.75 | 0.06936 | PITA; miRanda | -0.6 | 0 | NA | |
57 | hsa-miR-15b-5p | AKT3 | 1.62 | 0 | -0.75 | 0.06936 | miRNATAP | -0.36 | 0.00041 | NA | |
58 | hsa-miR-16-5p | AKT3 | 1.01 | 1.0E-5 | -0.75 | 0.06936 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.47 | 0.00031 | NA | |
59 | hsa-miR-17-3p | AKT3 | 1.31 | 0 | -0.75 | 0.06936 | miRNATAP | -0.52 | 0 | NA | |
60 | hsa-miR-17-5p | AKT3 | 1.66 | 0 | -0.75 | 0.06936 | TargetScan; miRNATAP | -0.28 | 0.0027 | NA | |
61 | hsa-miR-29a-3p | AKT3 | -0.11 | 0.61501 | -0.75 | 0.06936 | miRNATAP | -0.41 | 0.00212 | NA | |
62 | hsa-miR-29b-3p | AKT3 | -0.23 | 0.36746 | -0.75 | 0.06936 | miRNATAP | -0.34 | 0.00361 | 26512921 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3 |
63 | hsa-miR-32-3p | AKT3 | 0.58 | 0.11837 | -0.75 | 0.06936 | mirMAP | -0.32 | 0.00023 | NA | |
64 | hsa-miR-320b | AKT3 | 1.11 | 0.0005 | -0.75 | 0.06936 | PITA; miRanda; miRNATAP | -0.26 | 0.0039 | NA | |
65 | hsa-miR-335-3p | AKT3 | 2.52 | 0 | -0.75 | 0.06936 | mirMAP | -0.22 | 0.00074 | NA | |
66 | hsa-miR-33a-3p | AKT3 | 0.35 | 0.32171 | -0.75 | 0.06936 | mirMAP | -0.38 | 2.0E-5 | NA | |
67 | hsa-miR-362-3p | AKT3 | -0.03 | 0.91378 | -0.75 | 0.06936 | miRanda | -0.38 | 4.0E-5 | NA | |
68 | hsa-miR-362-5p | AKT3 | -0.35 | 0.35491 | -0.75 | 0.06936 | PITA; TargetScan; miRNATAP | -0.23 | 0.00253 | NA | |
69 | hsa-miR-501-3p | AKT3 | 0.73 | 0.02704 | -0.75 | 0.06936 | miRNATAP | -0.39 | 1.0E-5 | NA | |
70 | hsa-miR-502-3p | AKT3 | -0.16 | 0.55747 | -0.75 | 0.06936 | miRNATAP | -0.5 | 0 | NA | |
71 | hsa-miR-505-3p | AKT3 | 0.83 | 0.00112 | -0.75 | 0.06936 | mirMAP | -0.35 | 0.00235 | 22051041 | We also find that Akt3 correlate inversely with miR-505 modulates drug sensitivity in MCF7-ADR |
72 | hsa-miR-548v | AKT3 | -0.16 | 0.70867 | -0.75 | 0.06936 | miRNATAP | -0.27 | 0.00031 | NA | |
73 | hsa-miR-577 | AKT3 | 0.91 | 0.22561 | -0.75 | 0.06936 | mirMAP | -0.23 | 0 | NA | |
74 | hsa-miR-616-5p | AKT3 | 0.83 | 0.03478 | -0.75 | 0.06936 | mirMAP | -0.27 | 0.00041 | NA | |
75 | hsa-miR-429 | ANGPT1 | 1.4 | 0.009 | -0.53 | 0.28334 | miRanda | -0.3 | 0 | NA | |
76 | hsa-miR-129-5p | ANGPT2 | -2.57 | 0 | 1.7 | 0 | MirTarget; miRanda | -0.13 | 0.00318 | NA | |
77 | hsa-miR-145-5p | ANGPT2 | -1.75 | 2.0E-5 | 1.7 | 0 | MirTarget; miRNATAP | -0.22 | 0.00012 | 24384875; 27570490 | miR 145 functions as tumor suppressor and targets two oncogenes ANGPT2 and NEDD9 in renal cell carcinoma; We further validated those miR-145 targets two oncogenes ANGPT2 and NEDD9 in RCC;MiR 145 functions as a tumor suppressor via regulating angiopoietin 2 in pancreatic cancer cells; The direct action of miR-145 on Ang-2 was predicted by TargetScan and confirmed by luciferase report assay; The expression level of miR-145 was significantly lower and the expression levels of Ang-2 mRNA and protein was significantly higher in the more aggressive pancreatic cancer cells MiaPaCa-2 and Panc-1 when compared to that in BxPC3 cells; Overexpression of miR-145 in the BxPC3 MiaPaCa-2 and Panc-1 cells suppressed the cell invasion and colony formation ability and the expression level of Ang-2 protein in MiaPaCa-2 and Panc-1 cells was also suppressed after pre-miR-145 transfection; Intratumoral delivery of miR-145 inhibited the growth of pancreatic cancer xenografts and angiogenesis in vivo and also suppressed the expression level of angiopoietin-2 protein; MiR-145 functions as a tumor suppressor in pancreatic cancer cells by targeting Ang-2 for translation repression and thus suppresses pancreatic cancer cell invasion and growth which suggests that restoring of miR-145 may be a potential therapeutic target for pancreatic cancer |
78 | hsa-miR-664a-3p | ANGPT2 | -0.83 | 0.00014 | 1.7 | 0 | mirMAP | -0.37 | 0.00076 | NA | |
79 | hsa-miR-10a-3p | ARF6 | 0.22 | 0.56058 | 0.25 | 0.18203 | miRNATAP | -0.11 | 0.00124 | NA | |
80 | hsa-miR-181c-5p | ARF6 | 0.34 | 0.11293 | 0.25 | 0.18203 | MirTarget | -0.18 | 0.00393 | NA | |
81 | hsa-miR-181d-5p | ARF6 | 0.65 | 0.01434 | 0.25 | 0.18203 | MirTarget | -0.16 | 0.00106 | NA | |
82 | hsa-miR-217 | ARF6 | -0.01 | 0.98082 | 0.25 | 0.18203 | miRanda | -0.1 | 6.0E-5 | NA | |
83 | hsa-miR-30a-3p | ARF6 | -1.73 | 0 | 0.25 | 0.18203 | MirTarget; miRNATAP | -0.14 | 0.0002 | NA | |
84 | hsa-miR-30a-5p | ARF6 | -1.72 | 0 | 0.25 | 0.18203 | miRNAWalker2 validate | -0.16 | 3.0E-5 | NA | |
85 | hsa-miR-338-3p | ARF6 | -0.96 | 0.01915 | 0.25 | 0.18203 | miRanda | -0.14 | 1.0E-5 | NA | |
86 | hsa-miR-338-5p | ARF6 | -1.2 | 0.01003 | 0.25 | 0.18203 | PITA | -0.11 | 9.0E-5 | NA | |
87 | hsa-let-7b-5p | BCL2L1 | 0.06 | 0.7814 | 0.21 | 0.39578 | miRNATAP | -0.31 | 0.00027 | 26915294; 20347499 | As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;The let 7 family of microRNAs inhibits Bcl xL expression and potentiates sorafenib induced apoptosis in human hepatocellular carcinoma; The effect of let-7 on Bcl-xL expression was examined by Western blot and a reporter assay; Microarray analysis followed by in silico target prediction identified let-7 microRNAs as being downregulated in Huh7 hepatoma cells in comparison with primary human hepatocytes as well as possessing a putative target site in the bcl-xl mRNA |
88 | hsa-let-7c-5p | BCL2L1 | -0.5 | 0.20685 | 0.21 | 0.39578 | miRNAWalker2 validate; miRTarBase | -0.2 | 1.0E-5 | 20347499 | Over-expression of let-7c or let-7g led to a clear decrease of Bcl-xL expression in Huh7 and HepG2 cell lines; Reporter assays revealed direct post-transcriptional regulation involving let-7c or let-7g and the 3'-untranslated region of bcl-xl mRNA |
89 | hsa-miR-149-5p | BCL2L1 | 0.71 | 0.29685 | 0.21 | 0.39578 | mirMAP | -0.17 | 0 | NA | |
90 | hsa-miR-214-3p | BCL2L1 | 1.01 | 0.00625 | 0.21 | 0.39578 | mirMAP | -0.13 | 0.00824 | NA | |
91 | hsa-miR-23b-3p | BCL2L1 | -0.29 | 0.18665 | 0.21 | 0.39578 | miRNAWalker2 validate | -0.39 | 0 | NA | |
92 | hsa-miR-192-3p | BDNF | 0.36 | 0.74117 | 0.74 | 0.18381 | MirTarget; miRNATAP | -0.11 | 0.00424 | NA | |
93 | hsa-miR-29b-2-5p | BDNF | -1.7 | 0 | 0.74 | 0.18381 | mirMAP | -0.38 | 0.00762 | NA | |
94 | hsa-miR-338-5p | BDNF | -1.2 | 0.01003 | 0.74 | 0.18381 | miRNATAP | -0.3 | 0.00033 | NA | |
95 | hsa-let-7i-5p | CALM1 | 0.8 | 3.0E-5 | -0.7 | 3.0E-5 | miRNATAP | -0.2 | 0.00168 | NA | |
96 | hsa-miR-142-3p | CALM1 | 1.32 | 0.00015 | -0.7 | 3.0E-5 | miRanda; miRNATAP | -0.15 | 1.0E-5 | NA | |
97 | hsa-miR-142-5p | CALM1 | 1.56 | 1.0E-5 | -0.7 | 3.0E-5 | miRNATAP | -0.1 | 0.00342 | NA | |
98 | hsa-miR-15a-5p | CALM1 | 1.04 | 0 | -0.7 | 3.0E-5 | miRNATAP | -0.17 | 0.00311 | NA | |
99 | hsa-miR-16-2-3p | CALM1 | 1.8 | 0 | -0.7 | 3.0E-5 | mirMAP | -0.16 | 4.0E-5 | NA | |
100 | hsa-miR-16-5p | CALM1 | 1.01 | 1.0E-5 | -0.7 | 3.0E-5 | miRNATAP | -0.19 | 0.00043 | NA | |
101 | hsa-miR-181a-5p | CALM1 | 1.39 | 0 | -0.7 | 3.0E-5 | miRNATAP | -0.25 | 0 | NA | |
102 | hsa-miR-181b-5p | CALM1 | 1.64 | 0 | -0.7 | 3.0E-5 | miRNATAP | -0.21 | 0 | NA | |
103 | hsa-miR-181c-5p | CALM1 | 0.34 | 0.11293 | -0.7 | 3.0E-5 | miRNATAP | -0.28 | 0 | NA | |
104 | hsa-miR-186-5p | CALM1 | 0.15 | 0.43471 | -0.7 | 3.0E-5 | mirMAP | -0.2 | 0.00218 | NA | |
105 | hsa-miR-19a-3p | CALM1 | 1.27 | 0.00011 | -0.7 | 3.0E-5 | miRNATAP | -0.13 | 0.00055 | NA | |
106 | hsa-miR-19b-3p | CALM1 | 0.76 | 0.00653 | -0.7 | 3.0E-5 | miRNATAP | -0.16 | 0.00031 | NA | |
107 | hsa-miR-335-5p | CALM1 | 1.6 | 6.0E-5 | -0.7 | 3.0E-5 | mirMAP | -0.12 | 6.0E-5 | NA | |
108 | hsa-miR-3614-3p | CALM1 | 0.82 | 0.01436 | -0.7 | 3.0E-5 | miRNATAP | -0.12 | 0.0018 | NA | |
109 | hsa-miR-423-5p | CALM1 | 0.83 | 0.00079 | -0.7 | 3.0E-5 | miRNATAP | -0.13 | 0.00781 | NA | |
110 | hsa-miR-576-5p | CALM1 | 0.63 | 0.04171 | -0.7 | 3.0E-5 | mirMAP | -0.13 | 0.00155 | NA | |
111 | hsa-miR-7-1-3p | CALM1 | 0.71 | 0.04123 | -0.7 | 3.0E-5 | mirMAP | -0.1 | 0.00358 | NA | |
112 | hsa-let-7a-3p | CALM2 | 0.5 | 0.04111 | 0.38 | 0.00867 | miRNATAP | -0.11 | 0.00937 | NA | |
113 | hsa-miR-27a-3p | CALM3 | 1.3 | 0 | 0.14 | 0.45436 | miRNATAP | -0.23 | 5.0E-5 | NA | |
114 | hsa-miR-27b-3p | CALM3 | 0.08 | 0.72527 | 0.14 | 0.45436 | miRNAWalker2 validate; miRNATAP | -0.23 | 4.0E-5 | NA | |
115 | hsa-miR-34c-5p | CALM3 | 2.21 | 0.00038 | 0.14 | 0.45436 | miRanda | -0.11 | 0 | NA | |
116 | hsa-miR-411-5p | CALML4 | 0.02 | 0.95611 | 0.37 | 0.32957 | MirTarget | -0.34 | 1.0E-5 | NA | |
117 | hsa-miR-452-5p | CALML4 | 2.09 | 0.00026 | 0.37 | 0.32957 | mirMAP | -0.32 | 0 | NA | |
118 | hsa-miR-944 | CALML4 | 3.33 | 0.01778 | 0.37 | 0.32957 | PITA; miRNATAP | -0.22 | 0 | NA | |
119 | hsa-miR-152-3p | CHUK | 0.44 | 0.1617 | -0.11 | 0.43611 | MirTarget | -0.17 | 0 | NA | |
120 | hsa-miR-195-5p | CHUK | -0.91 | 0.00151 | -0.11 | 0.43611 | miRNAWalker2 validate; MirTarget | -0.13 | 0.00012 | NA | |
121 | hsa-miR-23a-3p | CHUK | 1.11 | 0 | -0.11 | 0.43611 | MirTarget | -0.17 | 0.00056 | NA | |
122 | hsa-miR-23b-3p | CHUK | -0.29 | 0.18665 | -0.11 | 0.43611 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.19 | 6.0E-5 | NA | |
123 | hsa-miR-342-3p | CHUK | 0.32 | 0.26915 | -0.11 | 0.43611 | miRanda | -0.19 | 0 | NA | |
124 | hsa-miR-497-5p | CHUK | -0.8 | 0.0036 | -0.11 | 0.43611 | MirTarget | -0.11 | 0.00273 | NA | |
125 | hsa-miR-106a-5p | CSF1 | -0.17 | 0.64287 | -0.31 | 0.33962 | miRNATAP | -0.17 | 0.00529 | NA | |
126 | hsa-miR-128-3p | CSF1 | 0.98 | 6.0E-5 | -0.31 | 0.33962 | MirTarget | -0.29 | 0.00152 | 22909061 | By mutations in putative miRNA targets in CSF-1 mRNA 3'UTR we identified a common target for both miR-128 and miR-152; We have also found that both miR-128 and miR-152 down-regulate CSF-1 mRNA and protein expression in ovarian cancer cells leading to decreased cell motility and adhesion in vitro two major aspects of the metastatic potential of cancer cells; Our results provide the evidence for a mechanism by which miR-128 and miR-152 down-regulate CSF-1 an important regulator of ovarian cancer |
127 | hsa-miR-130b-3p | CSF1 | 1.33 | 5.0E-5 | -0.31 | 0.33962 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.25 | 0.00031 | 22005523 | CSF-1 regulated by miR-130b was detected using Dual Luciferase Reporter system; CSF-1 expression was negatively associated with miR-130b level in ovarian tissues and cell lines; Luciferase assay validated CSF-1 is a direct target of miR-130b; Knock-down of CSF-1 sensitized ovarian cancer cells to anticancer drugs and could partially attenuate the resistance inducing effect of miR-130b inhibitors; Downregulation of miR-130b promotes the development of multidrug resistant ovarian cancer partially by targeting the 3'-UTR of CSF-1 and the silencing of miR-130b may be mediated by DNA methylation |
128 | hsa-miR-15b-5p | CSF1 | 1.62 | 0 | -0.31 | 0.33962 | miRNATAP | -0.24 | 0.00224 | NA | |
129 | hsa-miR-17-5p | CSF1 | 1.66 | 0 | -0.31 | 0.33962 | TargetScan; miRNATAP | -0.29 | 4.0E-5 | NA | |
130 | hsa-miR-20a-5p | CSF1 | 1.45 | 0 | -0.31 | 0.33962 | miRNATAP | -0.28 | 0.00019 | NA | |
131 | hsa-miR-23b-5p | CSF1 | 0.61 | 0.04865 | -0.31 | 0.33962 | MirTarget | -0.26 | 0.00073 | NA | |
132 | hsa-miR-301b-3p | CSF1 | 1.1 | 0.07156 | -0.31 | 0.33962 | MirTarget | -0.16 | 0.00197 | NA | |
133 | hsa-miR-429 | CSF1 | 1.4 | 0.009 | -0.31 | 0.33962 | PITA; miRanda; miRNATAP | -0.2 | 0 | NA | |
134 | hsa-miR-532-3p | CSF1 | 0.55 | 0.09755 | -0.31 | 0.33962 | MirTarget; PITA | -0.18 | 0.00784 | NA | |
135 | hsa-miR-940 | CSF1 | 1.64 | 0.00069 | -0.31 | 0.33962 | MirTarget; PITA; miRNATAP | -0.2 | 0.00032 | NA | |
136 | hsa-miR-96-5p | CSF1 | 1.14 | 0.00943 | -0.31 | 0.33962 | miRNATAP | -0.26 | 0 | NA | |
137 | hsa-miR-107 | CSF1R | 0.9 | 5.0E-5 | -1.02 | 0.01404 | miRanda | -0.55 | 4.0E-5 | NA | |
138 | hsa-miR-339-5p | CSF1R | 0.77 | 0.00817 | -1.02 | 0.01404 | miRanda | -0.27 | 0.00729 | NA | |
139 | hsa-miR-629-3p | CSF1R | 1.4 | 0.0001 | -1.02 | 0.01404 | MirTarget | -0.23 | 0.00448 | NA | |
140 | hsa-miR-30c-2-3p | EFNA1 | -1.14 | 0.00085 | 1 | 0.00013 | MirTarget | -0.2 | 0.00017 | NA | |
141 | hsa-miR-491-5p | EFNA1 | -0.69 | 0.03136 | 1 | 0.00013 | miRanda | -0.22 | 0.00026 | NA | |
142 | hsa-miR-205-5p | EFNA2 | 3.14 | 0.02932 | 2.57 | 0.01075 | MirTarget | -0.39 | 0 | NA | |
143 | hsa-miR-30a-5p | EFNA3 | -1.72 | 0 | 2.03 | 2.0E-5 | MirTarget; mirMAP; miRNATAP | -0.58 | 0 | NA | |
144 | hsa-miR-30c-5p | EFNA3 | -0.98 | 5.0E-5 | 2.03 | 2.0E-5 | MirTarget; mirMAP; miRNATAP | -0.63 | 1.0E-5 | NA | |
145 | hsa-miR-326 | EFNA3 | -0.43 | 0.26299 | 2.03 | 2.0E-5 | MirTarget; miRanda; miRNATAP | -0.31 | 0.00072 | NA | |
146 | hsa-miR-361-3p | EFNA3 | -0.13 | 0.56605 | 2.03 | 2.0E-5 | MirTarget; miRNATAP | -0.44 | 0.00675 | NA | |
147 | hsa-miR-140-5p | EFNA5 | 0.21 | 0.303 | -0.59 | 0.19744 | miRanda | -0.46 | 0.00594 | NA | |
148 | hsa-miR-186-5p | EFNA5 | 0.15 | 0.43471 | -0.59 | 0.19744 | mirMAP | -0.51 | 0.00337 | NA | |
149 | hsa-miR-19a-3p | EFNA5 | 1.27 | 0.00011 | -0.59 | 0.19744 | miRNATAP | -0.31 | 0.00145 | NA | |
150 | hsa-miR-19b-3p | EFNA5 | 0.76 | 0.00653 | -0.59 | 0.19744 | miRNATAP | -0.3 | 0.00979 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | INTRACELLULAR SIGNAL TRANSDUCTION | 106 | 1572 | 4.84e-80 | 2.252e-76 |
2 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 74 | 498 | 3.519e-77 | 8.187e-74 |
3 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 74 | 689 | 2.248e-66 | 3.487e-63 |
4 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 96 | 1791 | 4.515e-61 | 5.252e-58 |
5 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 89 | 1518 | 7.9e-59 | 6.127e-56 |
6 | PROTEIN PHOSPHORYLATION | 76 | 944 | 7.528e-59 | 6.127e-56 |
7 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 57 | 404 | 1.001e-56 | 6.654e-54 |
8 | PHOSPHORYLATION | 79 | 1228 | 5.411e-54 | 3.147e-51 |
9 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 93 | 1977 | 1.38e-53 | 7.135e-51 |
10 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 87 | 1656 | 3.274e-53 | 1.524e-50 |
11 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 90 | 1929 | 4.393e-51 | 1.858e-48 |
12 | POSITIVE REGULATION OF KINASE ACTIVITY | 54 | 482 | 5.33e-48 | 2.067e-45 |
13 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 65 | 876 | 4.725e-47 | 1.691e-44 |
14 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 68 | 1036 | 5.667e-46 | 1.758e-43 |
15 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 68 | 1036 | 5.667e-46 | 1.758e-43 |
16 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 69 | 1135 | 1.566e-44 | 4.554e-42 |
17 | REGULATION OF KINASE ACTIVITY | 60 | 776 | 4.084e-44 | 1.118e-41 |
18 | POSITIVE REGULATION OF CELL COMMUNICATION | 76 | 1532 | 2.103e-43 | 5.436e-41 |
19 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 77 | 1618 | 8.861e-43 | 2.17e-40 |
20 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 54 | 616 | 3.041e-42 | 7.075e-40 |
21 | REGULATION OF PROTEIN MODIFICATION PROCESS | 78 | 1710 | 4.209e-42 | 9.327e-40 |
22 | REGULATION OF MAPK CASCADE | 55 | 660 | 6.852e-42 | 1.449e-39 |
23 | POSITIVE REGULATION OF MAPK CASCADE | 49 | 470 | 9.008e-42 | 1.822e-39 |
24 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 72 | 1492 | 6.355e-40 | 1.232e-37 |
25 | REGULATION OF TRANSFERASE ACTIVITY | 60 | 946 | 3.971e-39 | 7.392e-37 |
26 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 58 | 905 | 5.988e-38 | 1.072e-35 |
27 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 31 | 138 | 5.443e-37 | 9.38e-35 |
28 | INOSITOL LIPID MEDIATED SIGNALING | 30 | 124 | 7.134e-37 | 1.186e-34 |
29 | REGULATION OF HYDROLASE ACTIVITY | 65 | 1327 | 6.995e-36 | 1.122e-33 |
30 | REGULATION OF GTPASE ACTIVITY | 50 | 673 | 2.031e-35 | 3.151e-33 |
31 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 40 | 352 | 2.345e-35 | 3.52e-33 |
32 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 44 | 470 | 2.726e-35 | 3.964e-33 |
33 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 37 | 289 | 1.316e-34 | 1.856e-32 |
34 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 71 | 1848 | 7.826e-33 | 1.071e-30 |
35 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 49 | 771 | 1.72e-31 | 2.287e-29 |
36 | PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 30 | 193 | 1.155e-30 | 1.493e-28 |
37 | POSITIVE REGULATION OF CELL PROLIFERATION | 49 | 814 | 2.118e-30 | 2.664e-28 |
38 | REGULATION OF MAP KINASE ACTIVITY | 35 | 319 | 2.409e-30 | 2.95e-28 |
39 | GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 34 | 297 | 4.183e-30 | 4.99e-28 |
40 | RAS PROTEIN SIGNAL TRANSDUCTION | 27 | 143 | 4.778e-30 | 5.558e-28 |
41 | RESPONSE TO ENDOGENOUS STIMULUS | 61 | 1450 | 1.001e-29 | 1.136e-27 |
42 | PHOSPHOLIPID METABOLIC PROCESS | 36 | 364 | 1.342e-29 | 1.487e-27 |
43 | GLYCEROLIPID METABOLIC PROCESS | 35 | 356 | 1.109e-28 | 1.2e-26 |
44 | POSITIVE REGULATION OF LOCOMOTION | 37 | 420 | 1.347e-28 | 1.425e-26 |
45 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 32 | 279 | 2.311e-28 | 2.39e-26 |
46 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 29 | 207 | 2.705e-28 | 2.736e-26 |
47 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 33 | 323 | 1.378e-27 | 1.364e-25 |
48 | REGULATION OF CELL PROLIFERATION | 59 | 1496 | 3.696e-27 | 3.582e-25 |
49 | LOCOMOTION | 52 | 1114 | 4.6e-27 | 4.368e-25 |
50 | RESPONSE TO GROWTH FACTOR | 37 | 475 | 1.124e-26 | 1.046e-24 |
51 | FC RECEPTOR SIGNALING PATHWAY | 27 | 206 | 1.425e-25 | 1.3e-23 |
52 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 24 | 142 | 1.501e-25 | 1.343e-23 |
53 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 60 | 1672 | 1.694e-25 | 1.488e-23 |
54 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 48 | 1008 | 3.149e-25 | 2.713e-23 |
55 | LIPID PHOSPHORYLATION | 21 | 99 | 1.131e-24 | 9.569e-23 |
56 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 17 | 49 | 2.803e-24 | 2.329e-22 |
57 | PEPTIDYL TYROSINE MODIFICATION | 25 | 186 | 5.294e-24 | 4.322e-22 |
58 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 46 | 1021 | 3.987e-23 | 3.198e-21 |
59 | RESPONSE TO EXTERNAL STIMULUS | 59 | 1821 | 9.346e-23 | 7.371e-21 |
60 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 52 | 1381 | 9.851e-23 | 7.64e-21 |
61 | TAXIS | 33 | 464 | 1.547e-22 | 1.18e-20 |
62 | RESPONSE TO NITROGEN COMPOUND | 42 | 859 | 2.185e-22 | 1.639e-20 |
63 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 47 | 1142 | 5.251e-22 | 3.879e-20 |
64 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 49 | 1275 | 1.032e-21 | 7.503e-20 |
65 | REGULATION OF VASCULATURE DEVELOPMENT | 25 | 233 | 1.564e-21 | 1.12e-19 |
66 | REGULATION OF CELL DEATH | 52 | 1472 | 1.764e-21 | 1.243e-19 |
67 | GLYCEROLIPID BIOSYNTHETIC PROCESS | 24 | 211 | 2.621e-21 | 1.82e-19 |
68 | REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 26 | 278 | 7.819e-21 | 5.351e-19 |
69 | REGULATION OF IMMUNE SYSTEM PROCESS | 50 | 1403 | 9.264e-21 | 6.247e-19 |
70 | PHOSPHOLIPID BIOSYNTHETIC PROCESS | 24 | 235 | 3.447e-20 | 2.292e-18 |
71 | BLOOD VESSEL MORPHOGENESIS | 28 | 364 | 4.362e-20 | 2.859e-18 |
72 | NEGATIVE REGULATION OF CELL DEATH | 39 | 872 | 2.12e-19 | 1.37e-17 |
73 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 31 | 505 | 2.539e-19 | 1.618e-17 |
74 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 48 | 1395 | 2.983e-19 | 1.876e-17 |
75 | VASCULATURE DEVELOPMENT | 30 | 469 | 3.273e-19 | 2.03e-17 |
76 | ORGANOPHOSPHATE METABOLIC PROCESS | 39 | 885 | 3.543e-19 | 2.169e-17 |
77 | CELL MOTILITY | 38 | 835 | 3.744e-19 | 2.234e-17 |
78 | LOCALIZATION OF CELL | 38 | 835 | 3.744e-19 | 2.234e-17 |
79 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 37 | 799 | 6.77e-19 | 3.987e-17 |
80 | CELL DEVELOPMENT | 48 | 1426 | 7.328e-19 | 4.262e-17 |
81 | REGULATION OF ENDOTHELIAL CELL MIGRATION | 18 | 114 | 7.864e-19 | 4.408e-17 |
82 | REGULATION OF ERK1 AND ERK2 CASCADE | 23 | 238 | 7.76e-19 | 4.408e-17 |
83 | REGULATION OF CELL DIFFERENTIATION | 49 | 1492 | 7.823e-19 | 4.408e-17 |
84 | REGULATION OF RAS PROTEIN SIGNAL TRANSDUCTION | 21 | 184 | 8.819e-19 | 4.885e-17 |
85 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 18 | 120 | 2.051e-18 | 1.123e-16 |
86 | NEUROGENESIS | 47 | 1402 | 2.234e-18 | 1.209e-16 |
87 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 36 | 788 | 3.394e-18 | 1.794e-16 |
88 | CIRCULATORY SYSTEM DEVELOPMENT | 36 | 788 | 3.394e-18 | 1.794e-16 |
89 | POSITIVE REGULATION OF ERK1 AND ERK2 CASCADE | 20 | 172 | 4.288e-18 | 2.242e-16 |
90 | ANGIOGENESIS | 24 | 293 | 6.076e-18 | 3.142e-16 |
91 | REGULATION OF IMMUNE RESPONSE | 37 | 858 | 7.043e-18 | 3.601e-16 |
92 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 37 | 867 | 9.9e-18 | 5.007e-16 |
93 | POSITIVE REGULATION OF VASCULATURE DEVELOPMENT | 18 | 133 | 1.377e-17 | 6.888e-16 |
94 | LIPID MODIFICATION | 21 | 210 | 1.393e-17 | 6.895e-16 |
95 | CELLULAR RESPONSE TO PEPTIDE | 23 | 274 | 1.825e-17 | 8.937e-16 |
96 | REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 21 | 213 | 1.868e-17 | 9.054e-16 |
97 | PEPTIDYL AMINO ACID MODIFICATION | 36 | 841 | 2.706e-17 | 1.298e-15 |
98 | PROTEIN AUTOPHOSPHORYLATION | 20 | 192 | 3.847e-17 | 1.827e-15 |
99 | REGULATION OF EPITHELIAL CELL MIGRATION | 19 | 166 | 4.149e-17 | 1.95e-15 |
100 | REGULATION OF TRANSPORT | 51 | 1804 | 6.878e-17 | 3.2e-15 |
101 | EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 13 | 55 | 2.393e-16 | 1.102e-14 |
102 | POSITIVE REGULATION OF CELL DIVISION | 17 | 132 | 2.69e-16 | 1.227e-14 |
103 | WOUND HEALING | 27 | 470 | 3.546e-16 | 1.602e-14 |
104 | CELLULAR LIPID METABOLIC PROCESS | 36 | 913 | 3.582e-16 | 1.603e-14 |
105 | RESPONSE TO WOUNDING | 29 | 563 | 4.458e-16 | 1.976e-14 |
106 | ACTIVATION OF MAPK ACTIVITY | 17 | 137 | 5.103e-16 | 2.24e-14 |
107 | REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 36 | 926 | 5.564e-16 | 2.419e-14 |
108 | REGULATION OF NEURON DEATH | 21 | 252 | 5.831e-16 | 2.512e-14 |
109 | CELL PROLIFERATION | 31 | 672 | 8.055e-16 | 3.439e-14 |
110 | ERBB SIGNALING PATHWAY | 14 | 79 | 1.253e-15 | 5.298e-14 |
111 | POSITIVE REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 13 | 62 | 1.308e-15 | 5.482e-14 |
112 | NEURON PROJECTION DEVELOPMENT | 28 | 545 | 1.629e-15 | 6.766e-14 |
113 | REGULATION OF PHOSPHOLIPASE ACTIVITY | 13 | 64 | 2.041e-15 | 8.403e-14 |
114 | REGULATION OF LIPASE ACTIVITY | 14 | 83 | 2.593e-15 | 1.058e-13 |
115 | REGULATION OF CELL PROJECTION ORGANIZATION | 28 | 558 | 2.953e-15 | 1.195e-13 |
116 | FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 14 | 84 | 3.091e-15 | 1.24e-13 |
117 | POSITIVE REGULATION OF LIPASE ACTIVITY | 13 | 66 | 3.135e-15 | 1.247e-13 |
118 | REGULATION OF CHEMOTAXIS | 18 | 180 | 3.253e-15 | 1.283e-13 |
119 | IMMUNE SYSTEM PROCESS | 51 | 1984 | 3.419e-15 | 1.337e-13 |
120 | CELL CELL SIGNALING | 32 | 767 | 4.358e-15 | 1.69e-13 |
121 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 33 | 823 | 4.723e-15 | 1.816e-13 |
122 | POSITIVE REGULATION OF PHOSPHOLIPASE ACTIVITY | 12 | 53 | 6.188e-15 | 2.36e-13 |
123 | RESPONSE TO HORMONE | 34 | 893 | 7.709e-15 | 2.916e-13 |
124 | REGULATION OF CELL ADHESION | 29 | 629 | 7.938e-15 | 2.979e-13 |
125 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 11 | 40 | 8.06e-15 | 3e-13 |
126 | RESPONSE TO PEPTIDE | 24 | 404 | 8.744e-15 | 3.229e-13 |
127 | POSITIVE REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 17 | 162 | 8.829e-15 | 3.235e-13 |
128 | NEURON DEVELOPMENT | 30 | 687 | 1.077e-14 | 3.916e-13 |
129 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 38 | 1152 | 1.46e-14 | 5.267e-13 |
130 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 31 | 750 | 1.608e-14 | 5.756e-13 |
131 | CELLULAR RESPONSE TO HORMONE STIMULUS | 27 | 552 | 1.821e-14 | 6.468e-13 |
132 | POSITIVE REGULATION OF CHEMOTAXIS | 15 | 120 | 2.583e-14 | 9.105e-13 |
133 | REGULATION OF CELL DIVISION | 20 | 272 | 3.303e-14 | 1.156e-12 |
134 | TISSUE DEVELOPMENT | 43 | 1518 | 3.678e-14 | 1.277e-12 |
135 | CELL PROJECTION ORGANIZATION | 33 | 902 | 6.329e-14 | 2.182e-12 |
136 | REGULATION OF LIPID KINASE ACTIVITY | 11 | 48 | 7.471e-14 | 2.556e-12 |
137 | LIPID BIOSYNTHETIC PROCESS | 26 | 539 | 8.117e-14 | 2.757e-12 |
138 | ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 24 | 450 | 9.313e-14 | 3.14e-12 |
139 | POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION | 12 | 67 | 1.268e-13 | 4.244e-12 |
140 | TUBE DEVELOPMENT | 26 | 552 | 1.409e-13 | 4.683e-12 |
141 | REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 11 | 51 | 1.544e-13 | 5.094e-12 |
142 | NEURON DIFFERENTIATION | 32 | 874 | 1.59e-13 | 5.211e-12 |
143 | ACTIVATION OF IMMUNE RESPONSE | 23 | 427 | 2.607e-13 | 8.483e-12 |
144 | REGULATION OF CELL DEVELOPMENT | 31 | 836 | 2.908e-13 | 9.396e-12 |
145 | REGULATION OF PHOSPHOLIPASE C ACTIVITY | 10 | 39 | 3.056e-13 | 9.741e-12 |
146 | POSITIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 10 | 39 | 3.056e-13 | 9.741e-12 |
147 | RESPONSE TO FIBROBLAST GROWTH FACTOR | 14 | 116 | 3.19e-13 | 1.01e-11 |
148 | PLATELET ACTIVATION | 15 | 142 | 3.23e-13 | 1.016e-11 |
149 | ORGAN MORPHOGENESIS | 31 | 841 | 3.402e-13 | 1.062e-11 |
150 | HEMOSTASIS | 20 | 311 | 4.095e-13 | 1.27e-11 |
151 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 12 | 74 | 4.428e-13 | 1.365e-11 |
152 | LIPID METABOLIC PROCESS | 36 | 1158 | 4.881e-13 | 1.494e-11 |
153 | POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 15 | 154 | 1.072e-12 | 3.259e-11 |
154 | INSULIN RECEPTOR SIGNALING PATHWAY | 12 | 80 | 1.168e-12 | 3.53e-11 |
155 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 11 | 61 | 1.268e-12 | 3.783e-11 |
156 | REGULATION OF RESPONSE TO STRESS | 40 | 1468 | 1.263e-12 | 3.783e-11 |
157 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 13 | 103 | 1.284e-12 | 3.806e-11 |
158 | REGULATION OF VESICLE MEDIATED TRANSPORT | 23 | 462 | 1.334e-12 | 3.929e-11 |
159 | EMBRYO DEVELOPMENT | 31 | 894 | 1.68e-12 | 4.916e-11 |
160 | LEUKOCYTE MIGRATION | 18 | 259 | 1.783e-12 | 5.184e-11 |
161 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 32 | 957 | 1.819e-12 | 5.258e-11 |
162 | REGULATION OF NEURON APOPTOTIC PROCESS | 16 | 192 | 2.058e-12 | 5.912e-11 |
163 | POSITIVE REGULATION OF CELL DEVELOPMENT | 23 | 472 | 2.072e-12 | 5.914e-11 |
164 | EPHRIN RECEPTOR SIGNALING PATHWAY | 12 | 85 | 2.468e-12 | 7.003e-11 |
165 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 19 | 303 | 2.568e-12 | 7.241e-11 |
166 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 16 | 195 | 2.612e-12 | 7.323e-11 |
167 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 31 | 917 | 3.24e-12 | 9.027e-11 |
168 | GLAND DEVELOPMENT | 21 | 395 | 3.973e-12 | 1.1e-10 |
169 | NEGATIVE REGULATION OF NEURON DEATH | 15 | 171 | 4.952e-12 | 1.363e-10 |
170 | CELL DEATH | 32 | 1001 | 5.964e-12 | 1.632e-10 |
171 | HEAD DEVELOPMENT | 27 | 709 | 6.69e-12 | 1.821e-10 |
172 | EPITHELIUM DEVELOPMENT | 31 | 945 | 7.013e-12 | 1.894e-10 |
173 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 28 | 767 | 7.043e-12 | 1.894e-10 |
174 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 21 | 408 | 7.334e-12 | 1.961e-10 |
175 | T CELL RECEPTOR SIGNALING PATHWAY | 14 | 146 | 7.788e-12 | 2.071e-10 |
176 | REGULATION OF NEURON DIFFERENTIATION | 24 | 554 | 7.898e-12 | 2.088e-10 |
177 | REGULATION OF CELLULAR LOCALIZATION | 36 | 1277 | 8.386e-12 | 2.204e-10 |
178 | CELLULAR COMPONENT MORPHOGENESIS | 30 | 900 | 1.09e-11 | 2.85e-10 |
179 | POSITIVE REGULATION OF IMMUNE RESPONSE | 24 | 563 | 1.106e-11 | 2.876e-10 |
180 | POSITIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 18 | 296 | 1.671e-11 | 4.319e-10 |
181 | REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 7 | 17 | 2.67e-11 | 6.864e-10 |
182 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 29 | 872 | 2.686e-11 | 6.867e-10 |
183 | POSITIVE REGULATION OF TRANSPORT | 30 | 936 | 2.872e-11 | 7.303e-10 |
184 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 12 | 106 | 3.592e-11 | 9.085e-10 |
185 | MORPHOGENESIS OF AN EPITHELIUM | 20 | 400 | 4.05e-11 | 1.019e-09 |
186 | NEGATIVE REGULATION OF NEURON APOPTOTIC PROCESS | 13 | 135 | 4.246e-11 | 1.062e-09 |
187 | REGULATION OF ENDOCYTOSIS | 15 | 199 | 4.384e-11 | 1.091e-09 |
188 | NEURON PROJECTION MORPHOGENESIS | 20 | 402 | 4.427e-11 | 1.096e-09 |
189 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 42 | 1805 | 4.985e-11 | 1.227e-09 |
190 | REGULATION OF AXONOGENESIS | 14 | 168 | 5.239e-11 | 1.283e-09 |
191 | RESPONSE TO ABIOTIC STIMULUS | 31 | 1024 | 5.348e-11 | 1.303e-09 |
192 | REGULATION OF CELL SUBSTRATE ADHESION | 14 | 173 | 7.768e-11 | 1.883e-09 |
193 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 17 | 285 | 8.539e-11 | 2.059e-09 |
194 | POSITIVE REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 6 | 11 | 8.797e-11 | 2.11e-09 |
195 | POSITIVE REGULATION OF LIPID KINASE ACTIVITY | 8 | 32 | 9.748e-11 | 2.326e-09 |
196 | REGULATION OF CELL MATRIX ADHESION | 11 | 90 | 1.041e-10 | 2.472e-09 |
197 | CELLULAR RESPONSE TO INSULIN STIMULUS | 13 | 146 | 1.145e-10 | 2.704e-09 |
198 | IMMUNE SYSTEM DEVELOPMENT | 23 | 582 | 1.397e-10 | 3.283e-09 |
199 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 18 | 337 | 1.407e-10 | 3.291e-09 |
200 | PLATELET DERIVED GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 8 | 34 | 1.661e-10 | 3.864e-09 |
201 | POSITIVE REGULATION OF DNA METABOLIC PROCESS | 14 | 185 | 1.902e-10 | 4.403e-09 |
202 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 20 | 437 | 1.945e-10 | 4.479e-09 |
203 | POSITIVE REGULATION OF PROTEIN AUTOPHOSPHORYLATION | 7 | 22 | 2.267e-10 | 5.196e-09 |
204 | POSITIVE CHEMOTAXIS | 8 | 36 | 2.732e-10 | 6.231e-09 |
205 | REGULATION OF CELL MORPHOGENESIS | 22 | 552 | 3.119e-10 | 7.079e-09 |
206 | PHOSPHATIDYLETHANOLAMINE ACYL CHAIN REMODELING | 7 | 23 | 3.237e-10 | 7.277e-09 |
207 | NEUROTROPHIN SIGNALING PATHWAY | 7 | 23 | 3.237e-10 | 7.277e-09 |
208 | POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 15 | 232 | 3.808e-10 | 8.519e-09 |
209 | REGULATION OF BODY FLUID LEVELS | 21 | 506 | 3.944e-10 | 8.781e-09 |
210 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 13 | 162 | 4.207e-10 | 9.322e-09 |
211 | CELLULAR RESPONSE TO GLUCAGON STIMULUS | 8 | 38 | 4.357e-10 | 9.609e-09 |
212 | REGULATION OF INTRACELLULAR TRANSPORT | 23 | 621 | 4.96e-10 | 1.089e-08 |
213 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 21 | 513 | 5.058e-10 | 1.105e-08 |
214 | ERBB2 SIGNALING PATHWAY | 8 | 39 | 5.446e-10 | 1.184e-08 |
215 | TUBE MORPHOGENESIS | 17 | 323 | 5.916e-10 | 1.28e-08 |
216 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 7 | 25 | 6.266e-10 | 1.35e-08 |
217 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 9 | 59 | 7.208e-10 | 1.546e-08 |
218 | RESPONSE TO INSULIN | 14 | 205 | 7.373e-10 | 1.574e-08 |
219 | POSITIVE REGULATION OF CELL ADHESION | 18 | 376 | 8.208e-10 | 1.744e-08 |
220 | REGULATION OF GLUCOSE IMPORT | 9 | 60 | 8.424e-10 | 1.782e-08 |
221 | PHOSPHATIDYLCHOLINE ACYL CHAIN REMODELING | 7 | 26 | 8.519e-10 | 1.794e-08 |
222 | REGULATION OF DEVELOPMENTAL GROWTH | 16 | 289 | 9.384e-10 | 1.967e-08 |
223 | POSITIVE REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 8 | 42 | 1.024e-09 | 2.128e-08 |
224 | POSITIVE REGULATION OF GLUCOSE TRANSPORT | 8 | 42 | 1.024e-09 | 2.128e-08 |
225 | REGULATION OF CYTOPLASMIC TRANSPORT | 20 | 481 | 1.035e-09 | 2.14e-08 |
226 | POSITIVE REGULATION OF DNA REPLICATION | 10 | 86 | 1.248e-09 | 2.569e-08 |
227 | PHOSPHATIDYLINOSITOL ACYL CHAIN REMODELING | 6 | 16 | 1.477e-09 | 3.027e-08 |
228 | REGULATION OF ORGANELLE ORGANIZATION | 31 | 1178 | 1.654e-09 | 3.376e-08 |
229 | CALCIUM MEDIATED SIGNALING | 10 | 90 | 1.963e-09 | 3.989e-08 |
230 | REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 6 | 17 | 2.268e-09 | 4.588e-08 |
231 | POSITIVE REGULATION OF AXONOGENESIS | 9 | 69 | 3.044e-09 | 6.131e-08 |
232 | CELL ACTIVATION | 21 | 568 | 3.122e-09 | 6.262e-08 |
233 | RESPONSE TO GLUCAGON | 8 | 48 | 3.149e-09 | 6.289e-08 |
234 | FC GAMMA RECEPTOR SIGNALING PATHWAY | 10 | 95 | 3.355e-09 | 6.671e-08 |
235 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 33 | 1360 | 3.415e-09 | 6.761e-08 |
236 | RESPONSE TO RADIATION | 18 | 413 | 3.618e-09 | 7.134e-08 |
237 | CELL PART MORPHOGENESIS | 22 | 633 | 3.953e-09 | 7.728e-08 |
238 | REGULATION OF GROWTH | 22 | 633 | 3.953e-09 | 7.728e-08 |
239 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 17 | 368 | 4.258e-09 | 8.29e-08 |
240 | POSITIVE REGULATION OF LIPID METABOLIC PROCESS | 11 | 128 | 4.736e-09 | 9.182e-08 |
241 | RESPONSE TO LIGHT STIMULUS | 15 | 280 | 5.045e-09 | 9.74e-08 |
242 | REGULATION OF GLUCOSE TRANSPORT | 10 | 100 | 5.56e-09 | 1.069e-07 |
243 | TISSUE MORPHOGENESIS | 20 | 533 | 5.966e-09 | 1.142e-07 |
244 | MORPHOGENESIS OF A BRANCHING STRUCTURE | 12 | 167 | 7.141e-09 | 1.362e-07 |
245 | NEURON PROJECTION GUIDANCE | 13 | 205 | 7.504e-09 | 1.425e-07 |
246 | RHYTHMIC PROCESS | 15 | 298 | 1.167e-08 | 2.208e-07 |
247 | REGULATION OF HOMEOSTATIC PROCESS | 18 | 447 | 1.237e-08 | 2.329e-07 |
248 | REGULATION OF PROTEIN AUTOPHOSPHORYLATION | 7 | 37 | 1.241e-08 | 2.329e-07 |
249 | ALCOHOL METABOLIC PROCESS | 16 | 348 | 1.335e-08 | 2.495e-07 |
250 | POSITIVE REGULATION OF NEURON DIFFERENTIATION | 15 | 306 | 1.663e-08 | 3.095e-07 |
251 | POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 6 | 23 | 1.78e-08 | 3.3e-07 |
252 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 5 | 12 | 1.987e-08 | 3.668e-07 |
253 | RESPONSE TO LIPID | 25 | 888 | 2.141e-08 | 3.937e-07 |
254 | PEPTIDYL SERINE MODIFICATION | 11 | 148 | 2.178e-08 | 3.99e-07 |
255 | HEART DEVELOPMENT | 18 | 466 | 2.341e-08 | 4.272e-07 |
256 | REGULATION OF POSITIVE CHEMOTAXIS | 6 | 24 | 2.358e-08 | 4.286e-07 |
257 | POSITIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 6 | 25 | 3.083e-08 | 5.582e-07 |
258 | MIDBRAIN DEVELOPMENT | 9 | 90 | 3.303e-08 | 5.957e-07 |
259 | PHOSPHATIDYLCHOLINE METABOLIC PROCESS | 8 | 64 | 3.327e-08 | 5.976e-07 |
260 | REGULATION OF LIPID METABOLIC PROCESS | 14 | 282 | 4.362e-08 | 7.806e-07 |
261 | SECOND MESSENGER MEDIATED SIGNALING | 11 | 160 | 4.883e-08 | 8.685e-07 |
262 | POSITIVE REGULATION OF CELL CYCLE | 15 | 332 | 4.89e-08 | 8.685e-07 |
263 | VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY | 5 | 14 | 4.959e-08 | 8.774e-07 |
264 | REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 6 | 27 | 5.088e-08 | 8.967e-07 |
265 | REGULATION OF CELL JUNCTION ASSEMBLY | 8 | 68 | 5.412e-08 | 9.503e-07 |
266 | PHOSPHATIDYLSERINE METABOLIC PROCESS | 6 | 28 | 6.434e-08 | 1.125e-06 |
267 | ACTIVATION OF INNATE IMMUNE RESPONSE | 12 | 204 | 6.647e-08 | 1.158e-06 |
268 | REGULATION OF DNA METABOLIC PROCESS | 15 | 340 | 6.679e-08 | 1.16e-06 |
269 | LIPID CATABOLIC PROCESS | 13 | 247 | 6.851e-08 | 1.185e-06 |
270 | REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 9 | 98 | 6.983e-08 | 1.203e-06 |
271 | NEUROTROPHIN TRK RECEPTOR SIGNALING PATHWAY | 5 | 15 | 7.392e-08 | 1.269e-06 |
272 | BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE | 10 | 131 | 7.548e-08 | 1.291e-06 |
273 | REGULATION OF PROTEIN LOCALIZATION | 25 | 950 | 7.914e-08 | 1.349e-06 |
274 | ACTIN FILAMENT BASED PROCESS | 17 | 450 | 8.114e-08 | 1.378e-06 |
275 | COGNITION | 13 | 251 | 8.264e-08 | 1.393e-06 |
276 | OSSIFICATION | 13 | 251 | 8.264e-08 | 1.393e-06 |
277 | MODULATION OF SYNAPTIC TRANSMISSION | 14 | 301 | 9.784e-08 | 1.644e-06 |
278 | POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 5 | 16 | 1.069e-07 | 1.788e-06 |
279 | STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 9 | 103 | 1.078e-07 | 1.797e-06 |
280 | POSITIVE REGULATION OF GENE EXPRESSION | 35 | 1733 | 1.091e-07 | 1.814e-06 |
281 | EMBRYONIC ORGAN DEVELOPMENT | 16 | 406 | 1.127e-07 | 1.866e-06 |
282 | GROWTH | 16 | 410 | 1.288e-07 | 2.125e-06 |
283 | CYTOSKELETON ORGANIZATION | 23 | 838 | 1.325e-07 | 2.179e-06 |
284 | PHOSPHATIDYLSERINE ACYL CHAIN REMODELING | 5 | 17 | 1.504e-07 | 2.454e-06 |
285 | REGULATION OF ACTIN CYTOSKELETON REORGANIZATION | 6 | 32 | 1.509e-07 | 2.454e-06 |
286 | PHOSPHATIDYLGLYCEROL ACYL CHAIN REMODELING | 5 | 17 | 1.504e-07 | 2.454e-06 |
287 | REGULATION OF ACTIN FILAMENT BASED PROCESS | 14 | 312 | 1.52e-07 | 2.464e-06 |
288 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 15 | 370 | 1.997e-07 | 3.227e-06 |
289 | ORGANIC HYDROXY COMPOUND METABOLIC PROCESS | 17 | 482 | 2.155e-07 | 3.47e-06 |
290 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 19 | 602 | 2.224e-07 | 3.568e-06 |
291 | POSITIVE REGULATION OF CELL DEATH | 19 | 605 | 2.4e-07 | 3.837e-06 |
292 | INOSITOL PHOSPHATE METABOLIC PROCESS | 7 | 56 | 2.473e-07 | 3.94e-06 |
293 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 22 | 801 | 2.529e-07 | 4.016e-06 |
294 | ALDITOL PHOSPHATE METABOLIC PROCESS | 6 | 35 | 2.651e-07 | 4.195e-06 |
295 | REGULATION OF CELL CELL ADHESION | 15 | 380 | 2.81e-07 | 4.432e-06 |
296 | VESICLE MEDIATED TRANSPORT | 28 | 1239 | 2.822e-07 | 4.436e-06 |
297 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 18 | 552 | 2.949e-07 | 4.62e-06 |
298 | REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORT | 9 | 116 | 3.005e-07 | 4.692e-06 |
299 | REGULATION OF CELL CYCLE | 24 | 949 | 3.074e-07 | 4.784e-06 |
300 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 18 | 554 | 3.109e-07 | 4.822e-06 |
301 | ETHANOLAMINE CONTAINING COMPOUND METABOLIC PROCESS | 8 | 85 | 3.153e-07 | 4.874e-06 |
302 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 10 | 153 | 3.247e-07 | 5.002e-06 |
303 | REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 9 | 118 | 3.478e-07 | 5.341e-06 |
304 | POSITIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORT | 7 | 59 | 3.567e-07 | 5.46e-06 |
305 | EMBRYONIC HEMOPOIESIS | 5 | 20 | 3.699e-07 | 5.643e-06 |
306 | POSITIVE REGULATION OF DEVELOPMENTAL GROWTH | 10 | 156 | 3.888e-07 | 5.912e-06 |
307 | HOMEOSTATIC PROCESS | 29 | 1337 | 3.922e-07 | 5.944e-06 |
308 | SINGLE ORGANISM BIOSYNTHETIC PROCESS | 29 | 1340 | 4.108e-07 | 6.198e-06 |
309 | POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 8 | 88 | 4.129e-07 | 6.198e-06 |
310 | REGULATION OF CATION CHANNEL ACTIVITY | 8 | 88 | 4.129e-07 | 6.198e-06 |
311 | APOPTOTIC SIGNALING PATHWAY | 13 | 289 | 4.188e-07 | 6.265e-06 |
312 | REGULATION OF ORGAN MORPHOGENESIS | 12 | 242 | 4.23e-07 | 6.308e-06 |
313 | REGULATION OF PROTEIN KINASE B SIGNALING | 9 | 121 | 4.309e-07 | 6.405e-06 |
314 | POSITIVE REGULATION OF CYCLASE ACTIVITY | 7 | 61 | 4.503e-07 | 6.673e-06 |
315 | REGULATION OF ION HOMEOSTASIS | 11 | 201 | 4.924e-07 | 7.273e-06 |
316 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 12 | 246 | 5.038e-07 | 7.418e-06 |
317 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 18 | 573 | 5.079e-07 | 7.455e-06 |
318 | SKELETAL SYSTEM DEVELOPMENT | 16 | 455 | 5.211e-07 | 7.578e-06 |
319 | ASTROCYTE DIFFERENTIATION | 6 | 39 | 5.194e-07 | 7.578e-06 |
320 | REGULATION OF DNA REPLICATION | 10 | 161 | 5.205e-07 | 7.578e-06 |
321 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 24 | 983 | 5.79e-07 | 8.393e-06 |
322 | NEGATIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 6 | 40 | 6.071e-07 | 8.746e-06 |
323 | POSITIVE REGULATION OF CELL MATRIX ADHESION | 6 | 40 | 6.071e-07 | 8.746e-06 |
324 | POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 15 | 406 | 6.499e-07 | 9.333e-06 |
325 | SYSTEM PROCESS | 34 | 1785 | 6.793e-07 | 9.696e-06 |
326 | EPIDERMIS DEVELOPMENT | 12 | 253 | 6.786e-07 | 9.696e-06 |
327 | REPRODUCTIVE SYSTEM DEVELOPMENT | 15 | 408 | 6.913e-07 | 9.836e-06 |
328 | REGULATION OF CALCIUM ION TRANSPORT | 11 | 209 | 7.252e-07 | 1.029e-05 |
329 | SECRETION | 18 | 588 | 7.375e-07 | 1.043e-05 |
330 | RESPONSE TO MECHANICAL STIMULUS | 11 | 210 | 7.603e-07 | 1.072e-05 |
331 | REGULATION OF INNATE IMMUNE RESPONSE | 14 | 357 | 7.724e-07 | 1.082e-05 |
332 | FOREBRAIN DEVELOPMENT | 14 | 357 | 7.724e-07 | 1.082e-05 |
333 | MYELOID LEUKOCYTE DIFFERENTIATION | 8 | 96 | 8.084e-07 | 1.13e-05 |
334 | PROTEIN LOCALIZATION | 34 | 1805 | 8.766e-07 | 1.221e-05 |
335 | RESPONSE TO OXYGEN LEVELS | 13 | 311 | 9.579e-07 | 1.327e-05 |
336 | POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 7 | 68 | 9.563e-07 | 1.327e-05 |
337 | REGULATION OF LONG TERM NEURONAL SYNAPTIC PLASTICITY | 5 | 24 | 9.89e-07 | 1.365e-05 |
338 | EMBRYONIC MORPHOGENESIS | 17 | 539 | 1.019e-06 | 1.403e-05 |
339 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 8 | 99 | 1.024e-06 | 1.405e-05 |
340 | CELLULAR RESPONSE TO STRESS | 31 | 1565 | 1.033e-06 | 1.414e-05 |
341 | CHEMICAL HOMEOSTASIS | 22 | 874 | 1.094e-06 | 1.493e-05 |
342 | GLIAL CELL DIFFERENTIATION | 9 | 136 | 1.157e-06 | 1.574e-05 |
343 | REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 7 | 70 | 1.167e-06 | 1.583e-05 |
344 | REGULATION OF VOLTAGE GATED CALCIUM CHANNEL ACTIVITY | 5 | 25 | 1.228e-06 | 1.662e-05 |
345 | SECRETION BY CELL | 16 | 486 | 1.239e-06 | 1.672e-05 |
346 | SPROUTING ANGIOGENESIS | 6 | 45 | 1.248e-06 | 1.673e-05 |
347 | SUBSTANTIA NIGRA DEVELOPMENT | 6 | 45 | 1.248e-06 | 1.673e-05 |
348 | REGULATED EXOCYTOSIS | 11 | 224 | 1.434e-06 | 1.917e-05 |
349 | REGULATION OF SYNAPTIC PLASTICITY | 9 | 140 | 1.474e-06 | 1.965e-05 |
350 | SENSORY ORGAN DEVELOPMENT | 16 | 493 | 1.493e-06 | 1.984e-05 |
351 | NEGATIVE REGULATION OF CELL COMMUNICATION | 26 | 1192 | 1.555e-06 | 2.061e-05 |
352 | CEREBRAL CORTEX DEVELOPMENT | 8 | 105 | 1.603e-06 | 2.119e-05 |
353 | POSITIVE REGULATION OF OXIDOREDUCTASE ACTIVITY | 6 | 47 | 1.624e-06 | 2.141e-05 |
354 | POSITIVE REGULATION OF CALCIUM ION TRANSPORT | 8 | 106 | 1.722e-06 | 2.264e-05 |
355 | REGULATION OF DEFENSE RESPONSE | 20 | 759 | 1.768e-06 | 2.318e-05 |
356 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 11 | 229 | 1.778e-06 | 2.324e-05 |
357 | SINGLE ORGANISM BEHAVIOR | 14 | 384 | 1.825e-06 | 2.379e-05 |
358 | RESPONSE TO AMINE | 6 | 48 | 1.844e-06 | 2.384e-05 |
359 | POSITIVE REGULATION OF ADENYLATE CYCLASE ACTIVITY | 6 | 48 | 1.844e-06 | 2.384e-05 |
360 | REGULATION OF SEQUESTERING OF CALCIUM ION | 8 | 107 | 1.849e-06 | 2.384e-05 |
361 | PLATELET DEGRANULATION | 8 | 107 | 1.849e-06 | 2.384e-05 |
362 | REGULATION OF CYTOSKELETON ORGANIZATION | 16 | 502 | 1.887e-06 | 2.425e-05 |
363 | REGULATION OF SYNAPSE STRUCTURE OR ACTIVITY | 11 | 232 | 2.018e-06 | 2.586e-05 |
364 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 12 | 282 | 2.117e-06 | 2.706e-05 |
365 | MYELOID CELL DIFFERENTIATION | 10 | 189 | 2.245e-06 | 2.862e-05 |
366 | VISUAL BEHAVIOR | 6 | 50 | 2.358e-06 | 2.99e-05 |
367 | PHAGOCYTOSIS | 10 | 190 | 2.354e-06 | 2.99e-05 |
368 | REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 7 | 78 | 2.443e-06 | 3.089e-05 |
369 | POSITIVE REGULATION OF GROWTH | 11 | 238 | 2.584e-06 | 3.258e-05 |
370 | SENSORY ORGAN MORPHOGENESIS | 11 | 239 | 2.691e-06 | 3.384e-05 |
371 | CELLULAR MACROMOLECULE LOCALIZATION | 26 | 1234 | 2.937e-06 | 3.684e-05 |
372 | ACTIVATION OF MAPKK ACTIVITY | 6 | 52 | 2.983e-06 | 3.731e-05 |
373 | LEUKOCYTE DIFFERENTIATION | 12 | 292 | 3.035e-06 | 3.786e-05 |
374 | RESPONSE TO AMPHETAMINE | 5 | 30 | 3.194e-06 | 3.931e-05 |
375 | PHOSPHOLIPID CATABOLIC PROCESS | 5 | 30 | 3.194e-06 | 3.931e-05 |
376 | NEPHRON DEVELOPMENT | 8 | 115 | 3.185e-06 | 3.931e-05 |
377 | OSTEOCLAST DIFFERENTIATION | 5 | 30 | 3.194e-06 | 3.931e-05 |
378 | CELLULAR RESPONSE TO VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULUS | 5 | 30 | 3.194e-06 | 3.931e-05 |
379 | RESPIRATORY SYSTEM DEVELOPMENT | 10 | 197 | 3.256e-06 | 3.997e-05 |
380 | REGULATION OF MORPHOGENESIS OF A BRANCHING STRUCTURE | 6 | 53 | 3.342e-06 | 4.081e-05 |
381 | MAMMARY GLAND EPITHELIUM DEVELOPMENT | 6 | 53 | 3.342e-06 | 4.081e-05 |
382 | JNK CASCADE | 7 | 82 | 3.425e-06 | 4.172e-05 |
383 | BONE DEVELOPMENT | 9 | 156 | 3.612e-06 | 4.388e-05 |
384 | POSITIVE REGULATION OF CALCIUM ION IMPORT | 6 | 54 | 3.736e-06 | 4.527e-05 |
385 | PHOSPHATIDYLGLYCEROL METABOLIC PROCESS | 5 | 31 | 3.784e-06 | 4.55e-05 |
386 | POSITIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 5 | 31 | 3.784e-06 | 4.55e-05 |
387 | HOMEOSTASIS OF NUMBER OF CELLS WITHIN A TISSUE | 5 | 31 | 3.784e-06 | 4.55e-05 |
388 | UROGENITAL SYSTEM DEVELOPMENT | 12 | 299 | 3.871e-06 | 4.642e-05 |
389 | REGULATION OF AUTOPHAGY | 11 | 249 | 3.991e-06 | 4.766e-05 |
390 | REGULATION OF CATABOLIC PROCESS | 19 | 731 | 3.995e-06 | 4.766e-05 |
391 | TISSUE MIGRATION | 7 | 84 | 4.028e-06 | 4.794e-05 |
392 | NUCLEAR TRANSPORT | 13 | 355 | 4.126e-06 | 4.897e-05 |
393 | CELL CHEMOTAXIS | 9 | 162 | 4.921e-06 | 5.826e-05 |
394 | REGULATION OF HOMOTYPIC CELL CELL ADHESION | 12 | 307 | 5.069e-06 | 5.986e-05 |
395 | PHOSPHATIDIC ACID METABOLIC PROCESS | 5 | 33 | 5.22e-06 | 6.149e-05 |
396 | POSITIVE REGULATION OF MITOTIC CELL CYCLE | 8 | 123 | 5.264e-06 | 6.185e-05 |
397 | REGULATION OF CATION TRANSMEMBRANE TRANSPORT | 10 | 208 | 5.279e-06 | 6.187e-05 |
398 | POSITIVE REGULATION OF DEFENSE RESPONSE | 13 | 364 | 5.412e-06 | 6.327e-05 |
399 | NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 7 | 88 | 5.502e-06 | 6.4e-05 |
400 | REGULATION OF STEM CELL PROLIFERATION | 7 | 88 | 5.502e-06 | 6.4e-05 |
401 | EXOCYTOSIS | 12 | 310 | 5.596e-06 | 6.494e-05 |
402 | POSITIVE REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 4 | 16 | 5.874e-06 | 6.799e-05 |
403 | EPITHELIAL CELL PROLIFERATION | 7 | 89 | 5.933e-06 | 6.851e-05 |
404 | NEGATIVE REGULATION OF CATION CHANNEL ACTIVITY | 5 | 34 | 6.082e-06 | 7.005e-05 |
405 | REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS | 6 | 59 | 6.313e-06 | 7.235e-05 |
406 | VASCULOGENESIS | 6 | 59 | 6.313e-06 | 7.235e-05 |
407 | REGULATION OF OXIDOREDUCTASE ACTIVITY | 7 | 90 | 6.392e-06 | 7.308e-05 |
408 | REGULATION OF G PROTEIN COUPLED RECEPTOR PROTEIN SIGNALING PATHWAY | 8 | 127 | 6.675e-06 | 7.593e-05 |
409 | POSITIVE REGULATION OF BINDING | 8 | 127 | 6.675e-06 | 7.593e-05 |
410 | AMMONIUM ION METABOLIC PROCESS | 9 | 169 | 6.943e-06 | 7.879e-05 |
411 | POSITIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 6 | 60 | 6.97e-06 | 7.891e-05 |
412 | NEGATIVE REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS | 5 | 35 | 7.052e-06 | 7.964e-05 |
413 | REGULATION OF CELLULAR RESPONSE TO STRESS | 18 | 691 | 7.092e-06 | 7.99e-05 |
414 | REPRODUCTION | 26 | 1297 | 7.198e-06 | 8.089e-05 |
415 | GLUCOSE HOMEOSTASIS | 9 | 170 | 7.283e-06 | 8.146e-05 |
416 | CARBOHYDRATE HOMEOSTASIS | 9 | 170 | 7.283e-06 | 8.146e-05 |
417 | POSITIVE REGULATION OF GLYCOGEN METABOLIC PROCESS | 4 | 17 | 7.635e-06 | 8.519e-05 |
418 | POSITIVE REGULATION OF LYASE ACTIVITY | 6 | 61 | 7.681e-06 | 8.53e-05 |
419 | POSITIVE REGULATION OF STEM CELL PROLIFERATION | 6 | 61 | 7.681e-06 | 8.53e-05 |
420 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 12 | 321 | 7.965e-06 | 8.824e-05 |
421 | NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 14 | 437 | 8.08e-06 | 8.93e-05 |
422 | REGULATION OF SECRETION | 18 | 699 | 8.295e-06 | 9.146e-05 |
423 | POSITIVE REGULATION OF TRANSMEMBRANE TRANSPORT | 8 | 131 | 8.392e-06 | 9.188e-05 |
424 | AMINE METABOLIC PROCESS | 8 | 131 | 8.392e-06 | 9.188e-05 |
425 | LEARNING | 8 | 131 | 8.392e-06 | 9.188e-05 |
426 | REGULATION OF METAL ION TRANSPORT | 12 | 325 | 9.023e-06 | 9.856e-05 |
427 | POLYOL METABOLIC PROCESS | 7 | 95 | 9.153e-06 | 9.974e-05 |
428 | GLIOGENESIS | 9 | 175 | 9.206e-06 | 9.985e-05 |
429 | HOMEOSTASIS OF NUMBER OF CELLS | 9 | 175 | 9.206e-06 | 9.985e-05 |
430 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 11 | 272 | 9.234e-06 | 9.992e-05 |
431 | POSITIVE REGULATION OF PURINE NUCLEOTIDE METABOLIC PROCESS | 8 | 133 | 9.382e-06 | 0.0001008 |
432 | POSITIVE REGULATION OF CATION CHANNEL ACTIVITY | 5 | 37 | 9.351e-06 | 0.0001008 |
433 | POSITIVE REGULATION OF NUCLEOTIDE METABOLIC PROCESS | 8 | 133 | 9.382e-06 | 0.0001008 |
434 | CELLULAR CHEMICAL HOMEOSTASIS | 16 | 570 | 9.445e-06 | 0.0001013 |
435 | NEGATIVE REGULATION OF TRANSPORTER ACTIVITY | 6 | 64 | 1.017e-05 | 0.0001088 |
436 | GLAND MORPHOGENESIS | 7 | 97 | 1.05e-05 | 0.0001118 |
437 | POSITIVE REGULATION OF CATION TRANSMEMBRANE TRANSPORT | 7 | 97 | 1.05e-05 | 0.0001118 |
438 | DEVELOPMENTAL GROWTH | 12 | 333 | 1.151e-05 | 0.0001223 |
439 | RESPONSE TO ALKALOID | 8 | 137 | 1.166e-05 | 0.0001236 |
440 | TELENCEPHALON DEVELOPMENT | 10 | 228 | 1.182e-05 | 0.000125 |
441 | POSITIVE REGULATION OF CELL SUBSTRATE ADHESION | 7 | 99 | 1.202e-05 | 0.0001268 |
442 | ACTIVATION OF ADENYLATE CYCLASE ACTIVITY | 5 | 39 | 1.22e-05 | 0.0001273 |
443 | REGULATION OF CARDIAC MUSCLE CONTRACTION BY REGULATION OF THE RELEASE OF SEQUESTERED CALCIUM ION | 4 | 19 | 1.228e-05 | 0.0001273 |
444 | POSITIVE REGULATION OF RELEASE OF SEQUESTERED CALCIUM ION INTO CYTOSOL | 5 | 39 | 1.22e-05 | 0.0001273 |
445 | KIDNEY VASCULATURE DEVELOPMENT | 4 | 19 | 1.228e-05 | 0.0001273 |
446 | NEURAL NUCLEUS DEVELOPMENT | 6 | 66 | 1.217e-05 | 0.0001273 |
447 | POSITIVE REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION | 4 | 19 | 1.228e-05 | 0.0001273 |
448 | RENAL SYSTEM VASCULATURE DEVELOPMENT | 4 | 19 | 1.228e-05 | 0.0001273 |
449 | PEPTIDYL TYROSINE AUTOPHOSPHORYLATION | 5 | 39 | 1.22e-05 | 0.0001273 |
450 | ESTABLISHMENT OF PROTEIN LOCALIZATION | 27 | 1423 | 1.271e-05 | 0.0001314 |
451 | POSITIVE REGULATION OF NEURON DEATH | 6 | 67 | 1.329e-05 | 0.0001371 |
452 | REGULATION OF BINDING | 11 | 283 | 1.339e-05 | 0.0001378 |
453 | NEGATIVE REGULATION OF TRANSPORT | 14 | 458 | 1.369e-05 | 0.0001406 |
454 | REGULATION OF CALCIUM ION IMPORT | 7 | 103 | 1.559e-05 | 0.0001597 |
455 | POSITIVE REGULATION OF ION TRANSPORT | 10 | 236 | 1.593e-05 | 0.000163 |
456 | DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS | 7 | 104 | 1.66e-05 | 0.0001694 |
457 | REGULATION OF ADENYLATE CYCLASE ACTIVITY | 6 | 70 | 1.713e-05 | 0.0001744 |
458 | REGULATION OF ENDOTHELIAL CELL APOPTOTIC PROCESS | 5 | 42 | 1.769e-05 | 0.0001797 |
459 | STEM CELL DIFFERENTIATION | 9 | 190 | 1.779e-05 | 0.0001803 |
460 | POSITIVE REGULATION OF ADHERENS JUNCTION ORGANIZATION | 4 | 21 | 1.874e-05 | 0.0001896 |
461 | POSITIVE REGULATION OF CELL CELL ADHESION | 10 | 243 | 2.05e-05 | 0.0002069 |
462 | ASSOCIATIVE LEARNING | 6 | 73 | 2.182e-05 | 0.0002197 |
463 | RESPONSE TO INORGANIC SUBSTANCE | 14 | 479 | 2.251e-05 | 0.0002256 |
464 | POSITIVE REGULATION OF LEUKOCYTE MIGRATION | 7 | 109 | 2.255e-05 | 0.0002256 |
465 | REGULATION OF RHO PROTEIN SIGNAL TRANSDUCTION | 7 | 109 | 2.255e-05 | 0.0002256 |
466 | SOMATIC STEM CELL DIVISION | 4 | 22 | 2.277e-05 | 0.0002269 |
467 | POSITIVE REGULATION OF NITRIC OXIDE SYNTHASE ACTIVITY | 4 | 22 | 2.277e-05 | 0.0002269 |
468 | REGULATION OF TRANSPORTER ACTIVITY | 9 | 198 | 2.465e-05 | 0.0002451 |
469 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 12 | 360 | 2.491e-05 | 0.0002458 |
470 | POSITIVE REGULATION OF RECEPTOR ACTIVITY | 5 | 45 | 2.493e-05 | 0.0002458 |
471 | EXOCRINE SYSTEM DEVELOPMENT | 5 | 45 | 2.493e-05 | 0.0002458 |
472 | REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 8 | 152 | 2.479e-05 | 0.0002458 |
473 | REGULATION OF CELL ACTIVATION | 14 | 484 | 2.523e-05 | 0.0002482 |
474 | CELLULAR GLUCOSE HOMEOSTASIS | 6 | 75 | 2.548e-05 | 0.0002496 |
475 | REGULATION OF RELEASE OF SEQUESTERED CALCIUM ION INTO CYTOSOL | 6 | 75 | 2.548e-05 | 0.0002496 |
476 | PALLIUM DEVELOPMENT | 8 | 153 | 2.599e-05 | 0.0002541 |
477 | RESPONSE TO ALCOHOL | 12 | 362 | 2.63e-05 | 0.0002566 |
478 | IMMUNE EFFECTOR PROCESS | 14 | 486 | 2.64e-05 | 0.000257 |
479 | RESPONSE TO AMINO ACID | 7 | 112 | 2.689e-05 | 0.0002612 |
480 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 12 | 363 | 2.702e-05 | 0.000262 |
481 | AMEBOIDAL TYPE CELL MIGRATION | 8 | 154 | 2.724e-05 | 0.0002635 |
482 | REGULATION OF CARDIAC MUSCLE CONTRACTION BY CALCIUM ION SIGNALING | 4 | 23 | 2.74e-05 | 0.0002645 |
483 | PEPTIDYL THREONINE MODIFICATION | 5 | 46 | 2.78e-05 | 0.0002678 |
484 | OVULATION CYCLE | 7 | 113 | 2.848e-05 | 0.0002732 |
485 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 12 | 365 | 2.852e-05 | 0.0002732 |
486 | REGULATION OF CELL PROJECTION ASSEMBLY | 8 | 155 | 2.853e-05 | 0.0002732 |
487 | REGULATION OF TRANSMEMBRANE TRANSPORT | 13 | 426 | 2.861e-05 | 0.0002734 |
488 | LYMPHOCYTE COSTIMULATION | 6 | 78 | 3.188e-05 | 0.000304 |
489 | IN UTERO EMBRYONIC DEVELOPMENT | 11 | 311 | 3.198e-05 | 0.0003043 |
490 | POSITIVE REGULATION OF CELL JUNCTION ASSEMBLY | 4 | 24 | 3.268e-05 | 0.0003097 |
491 | POSITIVE REGULATION OF RECEPTOR INTERNALIZATION | 4 | 24 | 3.268e-05 | 0.0003097 |
492 | RESPONSE TO STEROID HORMONE | 14 | 497 | 3.371e-05 | 0.0003188 |
493 | REGULATION OF RECEPTOR ACTIVITY | 7 | 117 | 3.564e-05 | 0.0003357 |
494 | MAMMARY GLAND DEVELOPMENT | 7 | 117 | 3.564e-05 | 0.0003357 |
495 | NEGATIVE REGULATION OF VASCULATURE DEVELOPMENT | 6 | 80 | 3.683e-05 | 0.0003462 |
496 | REGULATION OF NEURONAL SYNAPTIC PLASTICITY | 5 | 49 | 3.796e-05 | 0.0003546 |
497 | REGULATION OF NITRIC OXIDE SYNTHASE ACTIVITY | 5 | 49 | 3.796e-05 | 0.0003546 |
498 | GLOMERULUS DEVELOPMENT | 5 | 49 | 3.796e-05 | 0.0003546 |
499 | POSITIVE REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION | 4 | 25 | 3.867e-05 | 0.0003598 |
500 | REGULATION OF RELEASE OF SEQUESTERED CALCIUM ION INTO CYTOSOL BY SARCOPLASMIC RETICULUM | 4 | 25 | 3.867e-05 | 0.0003598 |
501 | REGULATION OF FIBROBLAST PROLIFERATION | 6 | 81 | 3.953e-05 | 0.0003664 |
502 | POSITIVE REGULATION OF PROTEIN KINASE B SIGNALING | 6 | 81 | 3.953e-05 | 0.0003664 |
503 | RESPONSE TO ACID CHEMICAL | 11 | 319 | 4.029e-05 | 0.0003727 |
504 | RESPONSE TO CYTOKINE | 17 | 714 | 4.05e-05 | 0.0003739 |
505 | REGULATION OF NUCLEOTIDE METABOLIC PROCESS | 9 | 211 | 4.059e-05 | 0.000374 |
506 | REGULATION OF ADHERENS JUNCTION ORGANIZATION | 5 | 50 | 4.191e-05 | 0.0003839 |
507 | FACE DEVELOPMENT | 5 | 50 | 4.191e-05 | 0.0003839 |
508 | REGULATION OF SYSTEM PROCESS | 14 | 507 | 4.185e-05 | 0.0003839 |
509 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 9 | 213 | 4.369e-05 | 0.0003993 |
510 | ORGAN REGENERATION | 6 | 83 | 4.539e-05 | 0.0004133 |
511 | EMBRYONIC PLACENTA DEVELOPMENT | 6 | 83 | 4.539e-05 | 0.0004133 |
512 | POSITIVE REGULATION OF MITOTIC NUCLEAR DIVISION | 5 | 51 | 4.618e-05 | 0.0004197 |
513 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 14 | 514 | 4.853e-05 | 0.0004401 |
514 | EYE DEVELOPMENT | 11 | 326 | 4.903e-05 | 0.0004438 |
515 | BEHAVIOR | 14 | 516 | 5.06e-05 | 0.0004571 |
516 | POSITIVE REGULATION OF CALCIUM ION TRANSPORT INTO CYTOSOL | 5 | 52 | 5.077e-05 | 0.0004579 |
517 | POSITIVE REGULATION OF HEART GROWTH | 4 | 27 | 5.3e-05 | 0.0004743 |
518 | REGULATION OF RYANODINE SENSITIVE CALCIUM RELEASE CHANNEL ACTIVITY | 4 | 27 | 5.3e-05 | 0.0004743 |
519 | POSITIVE REGULATION OF MESENCHYMAL CELL PROLIFERATION | 4 | 27 | 5.3e-05 | 0.0004743 |
520 | NEGATIVE REGULATION OF ENDOTHELIAL CELL APOPTOTIC PROCESS | 4 | 27 | 5.3e-05 | 0.0004743 |
521 | REGULATION OF LYASE ACTIVITY | 6 | 86 | 5.547e-05 | 0.0004947 |
522 | POSITIVE REGULATION OF FIBROBLAST PROLIFERATION | 5 | 53 | 5.571e-05 | 0.0004947 |
523 | NEGATIVE REGULATION OF CELL SUBSTRATE ADHESION | 5 | 53 | 5.571e-05 | 0.0004947 |
524 | CELLULAR RESPONSE TO AMINO ACID STIMULUS | 5 | 53 | 5.571e-05 | 0.0004947 |
525 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 9 | 220 | 5.613e-05 | 0.0004975 |
526 | TISSUE HOMEOSTASIS | 8 | 171 | 5.741e-05 | 0.0005078 |
527 | REGULATION OF ION TRANSPORT | 15 | 592 | 5.884e-05 | 0.0005195 |
528 | NEGATIVE REGULATION OF TRANSMEMBRANE TRANSPORT | 6 | 87 | 5.92e-05 | 0.0005217 |
529 | NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY | 4 | 28 | 6.146e-05 | 0.0005356 |
530 | REGULATION OF RHODOPSIN MEDIATED SIGNALING PATHWAY | 4 | 28 | 6.146e-05 | 0.0005356 |
531 | REGULATION OF SPROUTING ANGIOGENESIS | 4 | 28 | 6.146e-05 | 0.0005356 |
532 | MAMMARY GLAND DUCT MORPHOGENESIS | 4 | 28 | 6.146e-05 | 0.0005356 |
533 | B CELL RECEPTOR SIGNALING PATHWAY | 5 | 54 | 6.102e-05 | 0.0005356 |
534 | POSITIVE REGULATION OF PHOSPHATASE ACTIVITY | 4 | 28 | 6.146e-05 | 0.0005356 |
535 | OVULATION CYCLE PROCESS | 6 | 88 | 6.313e-05 | 0.000549 |
536 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 5 | 55 | 6.67e-05 | 0.000578 |
537 | ACTIN CYTOSKELETON REORGANIZATION | 5 | 55 | 6.67e-05 | 0.000578 |
538 | POSITIVE REGULATION OF CAMP METABOLIC PROCESS | 6 | 89 | 6.726e-05 | 0.0005807 |
539 | REGULATION OF GENERATION OF PRECURSOR METABOLITES AND ENERGY | 6 | 89 | 6.726e-05 | 0.0005807 |
540 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 13 | 465 | 7.008e-05 | 0.0006039 |
541 | REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION | 4 | 29 | 7.087e-05 | 0.0006051 |
542 | STEM CELL DIVISION | 4 | 29 | 7.087e-05 | 0.0006051 |
543 | POSITIVE REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT | 4 | 29 | 7.087e-05 | 0.0006051 |
544 | POSITIVE REGULATION OF MONOOXYGENASE ACTIVITY | 4 | 29 | 7.087e-05 | 0.0006051 |
545 | NEGATIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORT | 4 | 29 | 7.087e-05 | 0.0006051 |
546 | MUSCLE SYSTEM PROCESS | 10 | 282 | 7.211e-05 | 0.0006145 |
547 | NEURON NEURON SYNAPTIC TRANSMISSION | 5 | 56 | 7.279e-05 | 0.0006192 |
548 | CELLULAR HOMEOSTASIS | 16 | 676 | 7.401e-05 | 0.0006284 |
549 | ENDOTHELIAL CELL MIGRATION | 5 | 57 | 7.929e-05 | 0.0006708 |
550 | POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 8 | 179 | 7.916e-05 | 0.0006708 |
551 | REGULATION OF CALCIUM ION TRANSPORT INTO CYTOSOL | 6 | 92 | 8.098e-05 | 0.0006838 |
552 | ESTABLISHMENT OF LOCALIZATION IN CELL | 28 | 1676 | 8.405e-05 | 0.0007084 |
553 | REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 9 | 233 | 8.723e-05 | 0.000734 |
554 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 21 | 1079 | 9.193e-05 | 0.0007721 |
555 | REGULATION OF RAC PROTEIN SIGNAL TRANSDUCTION | 3 | 12 | 9.542e-05 | 0.0007971 |
556 | ACTIVATION OF TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE ACTIVITY | 3 | 12 | 9.542e-05 | 0.0007971 |
557 | NEGATIVE REGULATION OF RYANODINE SENSITIVE CALCIUM RELEASE CHANNEL ACTIVITY | 3 | 12 | 9.542e-05 | 0.0007971 |
558 | MITOTIC CELL CYCLE | 17 | 766 | 9.599e-05 | 0.0008004 |
559 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 20 | 1004 | 0.0001002 | 0.0008337 |
560 | REGULATION OF MONOOXYGENASE ACTIVITY | 5 | 60 | 0.0001015 | 0.000842 |
561 | REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 5 | 60 | 0.0001015 | 0.000842 |
562 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 21 | 1087 | 0.000102 | 0.0008442 |
563 | SALIVARY GLAND DEVELOPMENT | 4 | 32 | 0.0001054 | 0.0008709 |
564 | NEGATIVE REGULATION OF CATION TRANSMEMBRANE TRANSPORT | 5 | 61 | 0.0001099 | 0.000905 |
565 | OVARIAN FOLLICLE DEVELOPMENT | 5 | 61 | 0.0001099 | 0.000905 |
566 | NON CANONICAL WNT SIGNALING PATHWAY | 7 | 140 | 0.0001113 | 0.0009149 |
567 | RESPONSE TO TOXIC SUBSTANCE | 9 | 241 | 0.0001128 | 0.0009254 |
568 | MEMORY | 6 | 98 | 0.0001151 | 0.000941 |
569 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 6 | 98 | 0.0001151 | 0.000941 |
570 | REGULATION OF CELL CYCLE PROCESS | 14 | 558 | 0.0001161 | 0.0009474 |
571 | POSITIVE REGULATION OF NUCLEAR DIVISION | 5 | 62 | 0.0001188 | 0.000968 |
572 | CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 4 | 33 | 0.0001192 | 0.0009696 |
573 | MESENCHYME DEVELOPMENT | 8 | 190 | 0.0001199 | 0.0009733 |
574 | NEURONAL STEM CELL DIVISION | 3 | 13 | 0.0001233 | 0.0009929 |
575 | INDUCTION OF POSITIVE CHEMOTAXIS | 3 | 13 | 0.0001233 | 0.0009929 |
576 | HEPATOCYTE APOPTOTIC PROCESS | 3 | 13 | 0.0001233 | 0.0009929 |
577 | REGULATION OF CELL COMMUNICATION BY ELECTRICAL COUPLING | 3 | 13 | 0.0001233 | 0.0009929 |
578 | NEUROBLAST DIVISION | 3 | 13 | 0.0001233 | 0.0009929 |
579 | REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 6 | 100 | 0.0001287 | 0.001034 |
580 | FOREBRAIN NEURON DEVELOPMENT | 4 | 34 | 0.0001343 | 0.001073 |
581 | REGULATION OF MESENCHYMAL CELL PROLIFERATION | 4 | 34 | 0.0001343 | 0.001073 |
582 | PROTEIN KINASE B SIGNALING | 4 | 34 | 0.0001343 | 0.001073 |
583 | CONNECTIVE TISSUE DEVELOPMENT | 8 | 194 | 0.0001384 | 0.001105 |
584 | MUSCLE STRUCTURE DEVELOPMENT | 12 | 432 | 0.0001423 | 0.001134 |
585 | REGULATION OF MUSCLE SYSTEM PROCESS | 8 | 195 | 0.0001434 | 0.00114 |
586 | BONE REMODELING | 4 | 35 | 0.0001507 | 0.001192 |
587 | REGULATION OF GLYCOGEN METABOLIC PROCESS | 4 | 35 | 0.0001507 | 0.001192 |
588 | RESPONSE TO MINERALOCORTICOID | 4 | 35 | 0.0001507 | 0.001192 |
589 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 8 | 197 | 0.0001538 | 0.001215 |
590 | REGULATION OF RESPIRATORY BURST | 3 | 14 | 0.0001561 | 0.001225 |
591 | INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 3 | 14 | 0.0001561 | 0.001225 |
592 | BONE MATURATION | 3 | 14 | 0.0001561 | 0.001225 |
593 | DETECTION OF CALCIUM ION | 3 | 14 | 0.0001561 | 0.001225 |
594 | DIGESTIVE SYSTEM DEVELOPMENT | 7 | 148 | 0.0001573 | 0.001232 |
595 | SINGLE ORGANISM CATABOLIC PROCESS | 19 | 957 | 0.0001579 | 0.001235 |
596 | FOREBRAIN GENERATION OF NEURONS | 5 | 66 | 0.00016 | 0.001247 |
597 | REGULATION OF MULTICELLULAR ORGANISM GROWTH | 5 | 66 | 0.00016 | 0.001247 |
598 | POSITIVE REGULATION OF CELL ACTIVATION | 10 | 311 | 0.000161 | 0.001253 |
599 | REGULATION OF LEUKOCYTE MIGRATION | 7 | 149 | 0.000164 | 0.001274 |
600 | OLFACTORY LOBE DEVELOPMENT | 4 | 36 | 0.0001685 | 0.001305 |
601 | POSITIVE REGULATION OF GLUCOSE METABOLIC PROCESS | 4 | 36 | 0.0001685 | 0.001305 |
602 | ENDOCYTOSIS | 13 | 509 | 0.0001721 | 0.00133 |
603 | REGULATION OF TYROSINE PHOSPHORYLATION OF STAT PROTEIN | 5 | 68 | 0.0001844 | 0.001423 |
604 | REGULATION OF RECEPTOR INTERNALIZATION | 4 | 37 | 0.0001878 | 0.001442 |
605 | POSITIVE REGULATION OF TYROSINE PHOSPHORYLATION OF STAT3 PROTEIN | 4 | 37 | 0.0001878 | 0.001442 |
606 | REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION | 4 | 37 | 0.0001878 | 0.001442 |
607 | CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 3 | 15 | 0.000194 | 0.001481 |
608 | NEGATIVE REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION | 3 | 15 | 0.000194 | 0.001481 |
609 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 11 | 381 | 0.0001942 | 0.001481 |
610 | REGULATION OF HYDROGEN PEROXIDE METABOLIC PROCESS | 3 | 15 | 0.000194 | 0.001481 |
611 | REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 6 | 108 | 0.0001963 | 0.001495 |
612 | CELL CYCLE | 23 | 1316 | 0.0002059 | 0.001564 |
613 | POSITIVE REGULATION OF CYCLIC NUCLEOTIDE METABOLIC PROCESS | 6 | 109 | 0.0002064 | 0.001564 |
614 | RESPONSE TO HYDROGEN PEROXIDE | 6 | 109 | 0.0002064 | 0.001564 |
615 | POSITIVE REGULATION OF CALCIUM MEDIATED SIGNALING | 4 | 38 | 0.0002086 | 0.001573 |
616 | SUBSTRATE ADHESION DEPENDENT CELL SPREADING | 4 | 38 | 0.0002086 | 0.001573 |
617 | POSITIVE REGULATION OF ORGAN GROWTH | 4 | 38 | 0.0002086 | 0.001573 |
618 | REGULATION OF CYCLIC NUCLEOTIDE METABOLIC PROCESS | 7 | 155 | 0.0002091 | 0.001575 |
619 | NEGATIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 9 | 262 | 0.000211 | 0.001586 |
620 | CENTRAL NERVOUS SYSTEM NEURON DEVELOPMENT | 5 | 70 | 0.0002114 | 0.001587 |
621 | INFLAMMATORY RESPONSE | 12 | 454 | 0.0002249 | 0.001685 |
622 | SKIN EPIDERMIS DEVELOPMENT | 5 | 71 | 0.000226 | 0.001691 |
623 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 4 | 39 | 0.0002311 | 0.001718 |
624 | ANATOMICAL STRUCTURE MATURATION | 4 | 39 | 0.0002311 | 0.001718 |
625 | REGULATION OF CELL ADHESION MEDIATED BY INTEGRIN | 4 | 39 | 0.0002311 | 0.001718 |
626 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 4 | 39 | 0.0002311 | 0.001718 |
627 | SEX DIFFERENTIATION | 9 | 266 | 0.0002361 | 0.001752 |
628 | POSITIVE REGULATION OF SEQUESTERING OF CALCIUM ION | 3 | 16 | 0.0002374 | 0.001753 |
629 | CALCIUM MEDIATED SIGNALING USING INTRACELLULAR CALCIUM SOURCE | 3 | 16 | 0.0002374 | 0.001753 |
630 | BRANCHING INVOLVED IN SALIVARY GLAND MORPHOGENESIS | 3 | 16 | 0.0002374 | 0.001753 |
631 | SKIN DEVELOPMENT | 8 | 211 | 0.0002456 | 0.001811 |
632 | MAMMARY GLAND MORPHOGENESIS | 4 | 40 | 0.0002552 | 0.001879 |
633 | POSITIVE REGULATION OF STAT CASCADE | 5 | 73 | 0.0002575 | 0.001887 |
634 | REGULATION OF ORGAN GROWTH | 5 | 73 | 0.0002575 | 0.001887 |
635 | POSITIVE REGULATION OF JAK STAT CASCADE | 5 | 73 | 0.0002575 | 0.001887 |
636 | REGULATION OF EMBRYONIC DEVELOPMENT | 6 | 114 | 0.0002634 | 0.001927 |
637 | REGENERATION | 7 | 161 | 0.0002639 | 0.001928 |
638 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 5 | 74 | 0.0002745 | 0.002002 |
639 | RESPONSE TO CALCIUM ION | 6 | 115 | 0.0002761 | 0.002011 |
640 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 14 | 609 | 0.0002854 | 0.002075 |
641 | NEGATIVE REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 3 | 17 | 0.0002866 | 0.002078 |
642 | NEGATIVE REGULATION OF ANOIKIS | 3 | 17 | 0.0002866 | 0.002078 |
643 | DEVELOPMENT OF PRIMARY SEXUAL CHARACTERISTICS | 8 | 216 | 0.0002876 | 0.002081 |
644 | FEMALE SEX DIFFERENTIATION | 6 | 116 | 0.0002894 | 0.002091 |
645 | NEGATIVE REGULATION OF CYTOPLASMIC TRANSPORT | 6 | 117 | 0.0003031 | 0.002183 |
646 | NEGATIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 6 | 117 | 0.0003031 | 0.002183 |
647 | REGULATION OF CELLULAR COMPONENT SIZE | 10 | 337 | 0.0003064 | 0.002197 |
648 | RESPONSE TO ESTROGEN | 8 | 218 | 0.000306 | 0.002197 |
649 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 8 | 218 | 0.000306 | 0.002197 |
650 | POSITIVE REGULATION OF DNA BINDING | 4 | 42 | 0.0003088 | 0.002207 |
651 | REGULATION OF HEART GROWTH | 4 | 42 | 0.0003088 | 0.002207 |
652 | REGULATION OF CALCIUM MEDIATED SIGNALING | 5 | 76 | 0.0003109 | 0.002209 |
653 | POSITIVE REGULATION OF TRANSPORTER ACTIVITY | 5 | 76 | 0.0003109 | 0.002209 |
654 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 13 | 541 | 0.0003104 | 0.002209 |
655 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 13 | 541 | 0.0003104 | 0.002209 |
656 | MESODERM DEVELOPMENT | 6 | 118 | 0.0003173 | 0.002251 |
657 | REGULATION OF ANATOMICAL STRUCTURE SIZE | 12 | 472 | 0.0003202 | 0.002268 |
658 | REGULATION OF POLYSACCHARIDE METABOLIC PROCESS | 4 | 43 | 0.0003385 | 0.00239 |
659 | CEREBRAL CORTEX CELL MIGRATION | 4 | 43 | 0.0003385 | 0.00239 |
660 | REGULATION OF COLLATERAL SPROUTING | 3 | 18 | 0.000342 | 0.0024 |
661 | REGULATION OF PROTEIN BINDING | 7 | 168 | 0.0003417 | 0.0024 |
662 | ORGAN MATURATION | 3 | 18 | 0.000342 | 0.0024 |
663 | MAST CELL MEDIATED IMMUNITY | 3 | 18 | 0.000342 | 0.0024 |
664 | REGULATION OF DENDRITE DEVELOPMENT | 6 | 120 | 0.0003473 | 0.002434 |
665 | DIVALENT INORGANIC CATION HOMEOSTASIS | 10 | 343 | 0.0003522 | 0.002464 |
666 | NEGATIVE REGULATION OF CELL ADHESION | 8 | 223 | 0.0003562 | 0.002489 |
667 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 121 | 0.0003631 | 0.002533 |
668 | LABYRINTHINE LAYER DEVELOPMENT | 4 | 44 | 0.0003701 | 0.002574 |
669 | REGULATION OF TYROSINE PHOSPHORYLATION OF STAT3 PROTEIN | 4 | 44 | 0.0003701 | 0.002574 |
670 | DENDRITE DEVELOPMENT | 5 | 79 | 0.0003723 | 0.002585 |
671 | INTRACELLULAR PROTEIN TRANSPORT | 16 | 781 | 0.0003803 | 0.002633 |
672 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 7 | 171 | 0.0003803 | 0.002633 |
673 | ENDOCRINE SYSTEM DEVELOPMENT | 6 | 123 | 0.0003964 | 0.002741 |
674 | DENDRITIC SPINE DEVELOPMENT | 3 | 19 | 0.0004038 | 0.002772 |
675 | LUNG MORPHOGENESIS | 4 | 45 | 0.0004038 | 0.002772 |
676 | NEGATIVE REGULATION OF CALCIUM ION TRANSPORT INTO CYTOSOL | 3 | 19 | 0.0004038 | 0.002772 |
677 | MACROPHAGE DIFFERENTIATION | 3 | 19 | 0.0004038 | 0.002772 |
678 | NEGATIVE REGULATION OF CALCIUM MEDIATED SIGNALING | 3 | 19 | 0.0004038 | 0.002772 |
679 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 8 | 228 | 0.0004129 | 0.00283 |
680 | NEGATIVE REGULATION OF HOMEOSTATIC PROCESS | 6 | 124 | 0.000414 | 0.002833 |
681 | POSITIVE REGULATION OF MYELOID CELL DIFFERENTIATION | 5 | 81 | 0.000418 | 0.002852 |
682 | POSITIVE REGULATION OF LEUKOCYTE CHEMOTAXIS | 5 | 81 | 0.000418 | 0.002852 |
683 | RESPONSE TO OXIDATIVE STRESS | 10 | 352 | 0.0004316 | 0.002941 |
684 | CELLULAR RESPONSE TO ACID CHEMICAL | 7 | 175 | 0.000437 | 0.002973 |
685 | RESPONSE TO CORTICOSTEROID | 7 | 176 | 0.0004522 | 0.003072 |
686 | NEGATIVE REGULATION OF PHOSPHORYLATION | 11 | 422 | 0.0004627 | 0.003138 |
687 | REGULATION OF ERBB SIGNALING PATHWAY | 5 | 83 | 0.0004678 | 0.003159 |
688 | HAIR CYCLE | 5 | 83 | 0.0004678 | 0.003159 |
689 | MOLTING CYCLE | 5 | 83 | 0.0004678 | 0.003159 |
690 | NEGATIVE REGULATION OF ION TRANSPORT | 6 | 127 | 0.0004702 | 0.003171 |
691 | REGULATION OF SMOOTH MUSCLE CELL DIFFERENTIATION | 3 | 20 | 0.0004724 | 0.003181 |
692 | THYMUS DEVELOPMENT | 4 | 47 | 0.0004776 | 0.003193 |
693 | POSITIVE REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 4 | 47 | 0.0004776 | 0.003193 |
694 | MUSCLE CONTRACTION | 8 | 233 | 0.0004768 | 0.003193 |
695 | POSITIVE REGULATION OF DEPHOSPHORYLATION | 4 | 47 | 0.0004776 | 0.003193 |
696 | POSITIVE REGULATION OF GLIOGENESIS | 4 | 47 | 0.0004776 | 0.003193 |
697 | HEPATICOBILIARY SYSTEM DEVELOPMENT | 6 | 128 | 0.0004902 | 0.003273 |
698 | CYTOKINESIS | 5 | 84 | 0.0004944 | 0.003296 |
699 | REGULATION OF REPRODUCTIVE PROCESS | 6 | 129 | 0.0005109 | 0.003396 |
700 | REGULATION OF CAMP METABOLIC PROCESS | 6 | 129 | 0.0005109 | 0.003396 |
701 | REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT | 4 | 48 | 0.0005179 | 0.003428 |
702 | POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 4 | 48 | 0.0005179 | 0.003428 |
703 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO PLASMA MEMBRANE | 4 | 48 | 0.0005179 | 0.003428 |
704 | MAST CELL ACTIVATION | 3 | 21 | 0.000548 | 0.003617 |
705 | RUFFLE ORGANIZATION | 3 | 21 | 0.000548 | 0.003617 |
706 | POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 5 | 86 | 0.0005508 | 0.00363 |
707 | RESPONSE TO KETONE | 7 | 182 | 0.0005524 | 0.003636 |
708 | REGULATION OF MYELOID CELL DIFFERENTIATION | 7 | 183 | 0.0005707 | 0.003745 |
709 | REGULATION OF PROTEIN IMPORT | 7 | 183 | 0.0005707 | 0.003745 |
710 | B CELL ACTIVATION | 6 | 132 | 0.000577 | 0.003776 |
711 | POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 6 | 132 | 0.000577 | 0.003776 |
712 | POSITIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 4 | 50 | 0.0006057 | 0.003958 |
713 | NEGATIVE REGULATION OF CELL DEVELOPMENT | 9 | 303 | 0.0006089 | 0.003974 |
714 | SINGLE ORGANISM CELLULAR LOCALIZATION | 17 | 898 | 0.0006118 | 0.003987 |
715 | MORPHOGENESIS OF EMBRYONIC EPITHELIUM | 6 | 134 | 0.0006246 | 0.004059 |
716 | MESENCHYMAL CELL DIFFERENTIATION | 6 | 134 | 0.0006246 | 0.004059 |
717 | PROTEIN LOCALIZATION TO CELL SURFACE | 3 | 22 | 0.000631 | 0.004083 |
718 | SYNAPTIC TRANSMISSION GLUTAMATERGIC | 3 | 22 | 0.000631 | 0.004083 |
719 | ERK1 AND ERK2 CASCADE | 3 | 22 | 0.000631 | 0.004083 |
720 | REGULATION OF NEUROTRANSMITTER SECRETION | 4 | 51 | 0.0006533 | 0.004195 |
721 | RESPONSE TO NICOTINE | 4 | 51 | 0.0006533 | 0.004195 |
722 | INTERSPECIES INTERACTION BETWEEN ORGANISMS | 14 | 662 | 0.0006537 | 0.004195 |
723 | NEGATIVE REGULATION OF CALCIUM ION TRANSPORT | 4 | 51 | 0.0006533 | 0.004195 |
724 | SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM | 14 | 662 | 0.0006537 | 0.004195 |
725 | CELL GROWTH | 6 | 135 | 0.0006495 | 0.004195 |
726 | REGULATION OF PROTEIN TARGETING | 9 | 307 | 0.0006686 | 0.004285 |
727 | EYE MORPHOGENESIS | 6 | 136 | 0.0006752 | 0.004322 |
728 | ENDOTHELIUM DEVELOPMENT | 5 | 90 | 0.0006781 | 0.004322 |
729 | REGULATION OF GLIOGENESIS | 5 | 90 | 0.0006781 | 0.004322 |
730 | MESONEPHROS DEVELOPMENT | 5 | 90 | 0.0006781 | 0.004322 |
731 | POSITIVE REGULATION OF CELL CYCLE PROCESS | 8 | 247 | 0.0006994 | 0.004452 |
732 | REGULATION OF PROTEIN COMPLEX ASSEMBLY | 10 | 375 | 0.0007045 | 0.004478 |
733 | LYSOSOME LOCALIZATION | 3 | 23 | 0.0007215 | 0.004574 |
734 | REGULATION OF OSTEOBLAST PROLIFERATION | 3 | 23 | 0.0007215 | 0.004574 |
735 | PLACENTA DEVELOPMENT | 6 | 138 | 0.000729 | 0.004615 |
736 | RESPONSE TO REACTIVE OXYGEN SPECIES | 7 | 191 | 0.0007351 | 0.004647 |
737 | REGULATION OF NITRIC OXIDE BIOSYNTHETIC PROCESS | 4 | 53 | 0.0007564 | 0.004775 |
738 | DEVELOPMENTAL MATURATION | 7 | 193 | 0.0007815 | 0.004927 |
739 | REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL | 4 | 54 | 0.000812 | 0.005113 |
740 | NEGATIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 3 | 24 | 0.0008199 | 0.005135 |
741 | POLYSACCHARIDE CATABOLIC PROCESS | 3 | 24 | 0.0008199 | 0.005135 |
742 | BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 3 | 24 | 0.0008199 | 0.005135 |
743 | REGULATION OF ANOIKIS | 3 | 24 | 0.0008199 | 0.005135 |
744 | EAR DEVELOPMENT | 7 | 195 | 0.0008303 | 0.005193 |
745 | RESPONSE TO BACTERIUM | 12 | 528 | 0.000862 | 0.005384 |
746 | NEGATIVE REGULATION OF INTRACELLULAR TRANSPORT | 6 | 143 | 0.0008779 | 0.005476 |
747 | REGULATION OF JAK STAT CASCADE | 6 | 144 | 0.0009103 | 0.00564 |
748 | NEGATIVE REGULATION OF CELL PROJECTION ORGANIZATION | 6 | 144 | 0.0009103 | 0.00564 |
749 | REGULATION OF LEUKOCYTE CHEMOTAXIS | 5 | 96 | 0.0009087 | 0.00564 |
750 | REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 6 | 144 | 0.0009103 | 0.00564 |
751 | REGULATION OF STAT CASCADE | 6 | 144 | 0.0009103 | 0.00564 |
752 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 8 | 258 | 0.0009274 | 0.005708 |
753 | SINGLE ORGANISM CELL ADHESION | 11 | 459 | 0.0009238 | 0.005708 |
754 | NEGATIVE REGULATION OF CALCIUM ION IMPORT | 3 | 25 | 0.0009264 | 0.005708 |
755 | EPITHELIAL CELL APOPTOTIC PROCESS | 3 | 25 | 0.0009264 | 0.005708 |
756 | THYROID GLAND DEVELOPMENT | 3 | 25 | 0.0009264 | 0.005708 |
757 | REGULATION OF PROTEIN SECRETION | 10 | 389 | 0.0009313 | 0.005712 |
758 | REGULATION OF DENDRITIC SPINE DEVELOPMENT | 4 | 56 | 0.0009318 | 0.005712 |
759 | POSITIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT | 4 | 56 | 0.0009318 | 0.005712 |
760 | CELL DIVISION | 11 | 460 | 0.0009402 | 0.005756 |
761 | NEUROMUSCULAR PROCESS | 5 | 97 | 0.0009522 | 0.005822 |
762 | REGULATION OF CELL GROWTH | 10 | 391 | 0.0009681 | 0.005912 |
763 | RESPONSE TO ESTRADIOL | 6 | 146 | 0.0009778 | 0.005963 |
764 | REGULATION OF MUSCLE CONTRACTION | 6 | 147 | 0.001013 | 0.00617 |
765 | DEVELOPMENTAL PROGRAMMED CELL DEATH | 3 | 26 | 0.001041 | 0.006293 |
766 | REPLACEMENT OSSIFICATION | 3 | 26 | 0.001041 | 0.006293 |
767 | RESPONSE TO CORTICOSTERONE | 3 | 26 | 0.001041 | 0.006293 |
768 | ENDOCHONDRAL OSSIFICATION | 3 | 26 | 0.001041 | 0.006293 |
769 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 13 | 616 | 0.001039 | 0.006293 |
770 | REGULATION OF CELL FATE COMMITMENT | 3 | 26 | 0.001041 | 0.006293 |
771 | MYELOID LEUKOCYTE MIGRATION | 5 | 99 | 0.001044 | 0.006299 |
772 | REGULATION OF CYTOSOLIC CALCIUM ION CONCENTRATION | 7 | 203 | 0.00105 | 0.006311 |
773 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 8 | 263 | 0.001049 | 0.006311 |
774 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 7 | 203 | 0.00105 | 0.006311 |
775 | CELLULAR GLUCAN METABOLIC PROCESS | 4 | 58 | 0.001064 | 0.006377 |
776 | GLUCAN METABOLIC PROCESS | 4 | 58 | 0.001064 | 0.006377 |
777 | REGULATION OF MITOTIC CELL CYCLE | 11 | 468 | 0.00108 | 0.00647 |
778 | NEURAL TUBE DEVELOPMENT | 6 | 149 | 0.001086 | 0.00648 |
779 | NEGATIVE REGULATION OF HYDROLASE ACTIVITY | 10 | 397 | 0.001086 | 0.00648 |
780 | BIOLOGICAL ADHESION | 18 | 1032 | 0.001085 | 0.00648 |
781 | LIMBIC SYSTEM DEVELOPMENT | 5 | 100 | 0.001092 | 0.006505 |
782 | POSITIVE REGULATION OF DNA BIOSYNTHETIC PROCESS | 4 | 59 | 0.001134 | 0.006748 |
783 | REGULATION OF LEUKOCYTE PROLIFERATION | 7 | 206 | 0.001143 | 0.006783 |
784 | REGULATION OF EXTENT OF CELL GROWTH | 5 | 101 | 0.001142 | 0.006783 |
785 | REGULATION OF LAMELLIPODIUM ASSEMBLY | 3 | 27 | 0.001165 | 0.006905 |
786 | STEM CELL PROLIFERATION | 4 | 60 | 0.001208 | 0.007141 |
787 | CHONDROCYTE DIFFERENTIATION | 4 | 60 | 0.001208 | 0.007141 |
788 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 26 | 1784 | 0.001245 | 0.00735 |
789 | REGULATION OF PROTEIN TYROSINE KINASE ACTIVITY | 4 | 61 | 0.001285 | 0.007568 |
790 | CELLULAR RESPONSE TO HYDROGEN PEROXIDE | 4 | 61 | 0.001285 | 0.007568 |
791 | REGULATION OF NEUROBLAST PROLIFERATION | 3 | 28 | 0.001297 | 0.007631 |
792 | POSITIVE REGULATION OF PROTEIN IMPORT | 5 | 104 | 0.001301 | 0.007635 |
793 | CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES | 5 | 104 | 0.001301 | 0.007635 |
794 | FOREBRAIN CELL MIGRATION | 4 | 62 | 0.001365 | 0.007991 |
795 | REGULATION OF SMOOTHENED SIGNALING PATHWAY | 4 | 62 | 0.001365 | 0.007991 |
796 | NEGATIVE REGULATION OF RECEPTOR ACTIVITY | 3 | 29 | 0.001439 | 0.0084 |
797 | NEUROBLAST PROLIFERATION | 3 | 29 | 0.001439 | 0.0084 |
798 | REGULATION OF OSTEOCLAST DIFFERENTIATION | 4 | 63 | 0.001449 | 0.008449 |
799 | RESPONSE TO BIOTIC STIMULUS | 16 | 886 | 0.001451 | 0.008449 |
800 | POSITIVE REGULATION OF HOMEOSTATIC PROCESS | 7 | 216 | 0.001501 | 0.008731 |
801 | EMBRYONIC ORGAN MORPHOGENESIS | 8 | 279 | 0.001527 | 0.008869 |
802 | REGULATION OF CYTOKINESIS | 4 | 64 | 0.001537 | 0.008904 |
803 | REGULATION OF NEUROTRANSMITTER TRANSPORT | 4 | 64 | 0.001537 | 0.008904 |
804 | LEUKOCYTE DEGRANULATION | 3 | 30 | 0.00159 | 0.009109 |
805 | RESPONSE TO MORPHINE | 3 | 30 | 0.00159 | 0.009109 |
806 | RESPONSE TO EPIDERMAL GROWTH FACTOR | 3 | 30 | 0.00159 | 0.009109 |
807 | NEGATIVE REGULATION OF CELL MATRIX ADHESION | 3 | 30 | 0.00159 | 0.009109 |
808 | POSITIVE REGULATION OF SMOOTH MUSCLE CELL MIGRATION | 3 | 30 | 0.00159 | 0.009109 |
809 | MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 30 | 0.00159 | 0.009109 |
810 | REGULATION OF DENDRITIC SPINE MORPHOGENESIS | 3 | 30 | 0.00159 | 0.009109 |
811 | RESPONSE TO ISOQUINOLINE ALKALOID | 3 | 30 | 0.00159 | 0.009109 |
812 | REGULATION OF VASCULAR PERMEABILITY | 3 | 30 | 0.00159 | 0.009109 |
813 | REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 4 | 65 | 0.001628 | 0.009304 |
814 | NEGATIVE REGULATION OF AXONOGENESIS | 4 | 65 | 0.001628 | 0.009304 |
815 | POSITIVE REGULATION OF SYNAPTIC TRANSMISSION | 5 | 110 | 0.001669 | 0.009527 |
816 | EPITHELIAL CELL DIFFERENTIATION | 11 | 495 | 0.001687 | 0.009622 |
817 | WNT SIGNALING PATHWAY | 9 | 351 | 0.001701 | 0.009685 |
818 | ACID SECRETION | 4 | 66 | 0.001722 | 0.009773 |
819 | REGULATION OF CARDIAC MUSCLE CONTRACTION | 4 | 66 | 0.001722 | 0.009773 |
820 | REGULATION OF CARDIAC CONDUCTION | 4 | 66 | 0.001722 | 0.009773 |
821 | ANATOMICAL STRUCTURE HOMEOSTASIS | 8 | 285 | 0.001745 | 0.00989 |
822 | EYE PHOTORECEPTOR CELL DEVELOPMENT | 3 | 31 | 0.00175 | 0.009894 |
823 | REGULATION OF SYNAPTIC VESICLE TRANSPORT | 3 | 31 | 0.00175 | 0.009894 |
824 | SYNAPTIC SIGNALING | 10 | 424 | 0.00177 | 0.009993 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | KINASE ACTIVITY | 59 | 842 | 7.3e-41 | 6.781e-38 |
2 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 59 | 992 | 7.606e-37 | 3.533e-34 |
3 | PROTEIN KINASE ACTIVITY | 48 | 640 | 4.082e-34 | 1.264e-31 |
4 | RAS GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 33 | 228 | 1.184e-32 | 2.749e-30 |
5 | GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 36 | 303 | 1.791e-32 | 3.328e-30 |
6 | MOLECULAR FUNCTION REGULATOR | 62 | 1353 | 2.276e-32 | 3.524e-30 |
7 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 22 | 70 | 4.905e-30 | 6.51e-28 |
8 | RECEPTOR BINDING | 58 | 1476 | 1.445e-26 | 1.678e-24 |
9 | PROTEIN TYROSINE KINASE ACTIVITY | 26 | 176 | 4.899e-26 | 5.057e-24 |
10 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 17 | 43 | 1.889e-25 | 1.755e-23 |
11 | GROWTH FACTOR ACTIVITY | 24 | 160 | 2.999e-24 | 2.533e-22 |
12 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 17 | 51 | 6.288e-24 | 4.868e-22 |
13 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE ACTIVITY | 17 | 64 | 5.392e-22 | 3.853e-20 |
14 | RIBONUCLEOTIDE BINDING | 58 | 1860 | 1.665e-21 | 1.105e-19 |
15 | SIGNAL TRANSDUCER ACTIVITY | 56 | 1731 | 1.915e-21 | 1.186e-19 |
16 | TRANSMEMBRANE RECEPTOR PROTEIN KINASE ACTIVITY | 17 | 81 | 4.492e-20 | 2.608e-18 |
17 | ENZYME BINDING | 54 | 1737 | 8.118e-20 | 4.436e-18 |
18 | KINASE BINDING | 33 | 606 | 5.781e-19 | 2.984e-17 |
19 | RECEPTOR SIGNALING PROTEIN ACTIVITY | 20 | 172 | 4.288e-18 | 2.096e-16 |
20 | GROWTH FACTOR RECEPTOR BINDING | 16 | 129 | 3.875e-15 | 1.8e-13 |
21 | PROTEIN TYROSINE KINASE BINDING | 12 | 54 | 7.903e-15 | 3.496e-13 |
22 | NEUROTROPHIN RECEPTOR BINDING | 8 | 14 | 3.131e-14 | 1.322e-12 |
23 | ADENYL NUCLEOTIDE BINDING | 43 | 1514 | 3.357e-14 | 1.356e-12 |
24 | PHOSPHOLIPASE ACTIVITY | 13 | 94 | 3.836e-13 | 1.485e-11 |
25 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 23 | 445 | 6.151e-13 | 2.286e-11 |
26 | GTPASE ACTIVITY | 18 | 246 | 7.436e-13 | 2.657e-11 |
27 | RECEPTOR SIGNALING PROTEIN SERINE THREONINE KINASE ACTIVITY | 12 | 92 | 6.499e-12 | 2.236e-10 |
28 | LIPASE ACTIVITY | 13 | 117 | 6.769e-12 | 2.246e-10 |
29 | GROWTH FACTOR BINDING | 13 | 123 | 1.291e-11 | 4.134e-10 |
30 | ENZYME ACTIVATOR ACTIVITY | 22 | 471 | 1.493e-11 | 4.624e-10 |
31 | FIBROBLAST GROWTH FACTOR RECEPTOR BINDING | 8 | 28 | 2.957e-11 | 8.861e-10 |
32 | KINASE ACTIVATOR ACTIVITY | 10 | 62 | 4.44e-11 | 1.289e-09 |
33 | ENZYME REGULATOR ACTIVITY | 30 | 959 | 5.205e-11 | 1.465e-09 |
34 | INSULIN RECEPTOR SUBSTRATE BINDING | 6 | 11 | 8.797e-11 | 2.404e-09 |
35 | KINASE REGULATOR ACTIVITY | 14 | 186 | 2.043e-10 | 5.423e-09 |
36 | PHOSPHATIDYLINOSITOL 3 KINASE BINDING | 7 | 30 | 2.569e-09 | 6.629e-08 |
37 | PHOSPHOLIPASE A2 ACTIVITY | 7 | 31 | 3.297e-09 | 8.278e-08 |
38 | PROTEIN SERINE THREONINE KINASE ACTIVATOR ACTIVITY | 6 | 19 | 4.908e-09 | 1.2e-07 |
39 | PHOSPHATIDYLCHOLINE 1 ACYLHYDROLASE ACTIVITY | 5 | 11 | 1.166e-08 | 2.778e-07 |
40 | HEPARIN BINDING | 11 | 157 | 4.017e-08 | 9.329e-07 |
41 | THIOESTERASE BINDING | 5 | 14 | 4.959e-08 | 1.124e-06 |
42 | CHEMOATTRACTANT ACTIVITY | 6 | 27 | 5.088e-08 | 1.125e-06 |
43 | GUANYL NUCLEOTIDE BINDING | 16 | 390 | 6.504e-08 | 1.405e-06 |
44 | INSULIN LIKE GROWTH FACTOR RECEPTOR BINDING | 5 | 15 | 7.392e-08 | 1.526e-06 |
45 | PLATELET DERIVED GROWTH FACTOR RECEPTOR BINDING | 5 | 15 | 7.392e-08 | 1.526e-06 |
46 | INSULIN RECEPTOR BINDING | 6 | 32 | 1.509e-07 | 2.982e-06 |
47 | GTP DEPENDENT PROTEIN BINDING | 5 | 17 | 1.504e-07 | 2.982e-06 |
48 | CYTOKINE RECEPTOR BINDING | 13 | 271 | 2.008e-07 | 3.886e-06 |
49 | SULFUR COMPOUND BINDING | 12 | 234 | 2.951e-07 | 5.595e-06 |
50 | GLYCOSAMINOGLYCAN BINDING | 11 | 205 | 5.989e-07 | 1.113e-05 |
51 | EPHRIN RECEPTOR BINDING | 5 | 24 | 9.89e-07 | 1.801e-05 |
52 | GDP BINDING | 6 | 51 | 2.655e-06 | 4.744e-05 |
53 | MAP KINASE ACTIVITY | 4 | 14 | 3.27e-06 | 5.732e-05 |
54 | PROTEIN HETERODIMERIZATION ACTIVITY | 15 | 468 | 3.76e-06 | 6.469e-05 |
55 | PROTEIN PHOSPHATASE BINDING | 8 | 120 | 4.38e-06 | 7.398e-05 |
56 | PHOSPHATASE BINDING | 9 | 162 | 4.921e-06 | 8.163e-05 |
57 | IDENTICAL PROTEIN BINDING | 25 | 1209 | 6.491e-06 | 0.0001058 |
58 | PROTEIN DIMERIZATION ACTIVITY | 24 | 1149 | 8.608e-06 | 0.0001379 |
59 | GLUTAMATE RECEPTOR BINDING | 5 | 37 | 9.351e-06 | 0.0001472 |
60 | NUCLEOSIDE TRIPHOSPHATASE REGULATOR ACTIVITY | 12 | 329 | 1.02e-05 | 0.000158 |
61 | CARBOXYLIC ESTER HYDROLASE ACTIVITY | 8 | 135 | 1.047e-05 | 0.0001594 |
62 | PROTEIN COMPLEX BINDING | 21 | 935 | 1.141e-05 | 0.000171 |
63 | PROTEIN SERINE THREONINE TYROSINE KINASE ACTIVITY | 5 | 39 | 1.22e-05 | 0.0001783 |
64 | PHOSPHOLIPASE BINDING | 4 | 19 | 1.228e-05 | 0.0001783 |
65 | PROTEIN N TERMINUS BINDING | 7 | 103 | 1.559e-05 | 0.0002228 |
66 | HYDROLASE ACTIVITY ACTING ON ACID ANHYDRIDES | 19 | 820 | 2.018e-05 | 0.0002841 |
67 | SIGNALING ADAPTOR ACTIVITY | 6 | 74 | 2.359e-05 | 0.0003271 |
68 | PROTEIN DOMAIN SPECIFIC BINDING | 16 | 624 | 2.861e-05 | 0.0003909 |
69 | PHOSPHATASE ACTIVATOR ACTIVITY | 3 | 11 | 7.197e-05 | 0.0009417 |
70 | DIACYLGLYCEROL BINDING | 3 | 11 | 7.197e-05 | 0.0009417 |
71 | INOSITOL TRISPHOSPHATE KINASE ACTIVITY | 3 | 11 | 7.197e-05 | 0.0009417 |
72 | CALCIUM DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 12 | 9.542e-05 | 0.001214 |
73 | MAP KINASE KINASE ACTIVITY | 3 | 12 | 9.542e-05 | 0.001214 |
74 | GTPASE BINDING | 10 | 295 | 0.0001046 | 0.001314 |
75 | PROTEIN HOMODIMERIZATION ACTIVITY | 16 | 722 | 0.0001581 | 0.001933 |
76 | TITIN BINDING | 3 | 14 | 0.0001561 | 0.001933 |
77 | PROTEIN KINASE C ACTIVITY | 3 | 16 | 0.0002374 | 0.002828 |
78 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY | 3 | 16 | 0.0002374 | 0.002828 |
79 | NITRIC OXIDE SYNTHASE BINDING | 3 | 19 | 0.0004038 | 0.004749 |
80 | LYSOPHOSPHOLIPASE ACTIVITY | 3 | 20 | 0.0004724 | 0.005486 |
81 | HYDROLASE ACTIVITY ACTING ON ESTER BONDS | 15 | 739 | 0.0006398 | 0.007338 |
82 | PHOSPHORIC DIESTER HYDROLASE ACTIVITY | 5 | 90 | 0.0006781 | 0.007682 |
83 | FIBROBLAST GROWTH FACTOR BINDING | 3 | 23 | 0.0007215 | 0.008076 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | CYTOPLASMIC SIDE OF MEMBRANE | 22 | 170 | 7.602e-21 | 4.44e-18 |
2 | SIDE OF MEMBRANE | 25 | 428 | 3.374e-15 | 9.852e-13 |
3 | EXTRINSIC COMPONENT OF MEMBRANE | 19 | 252 | 9.585e-14 | 1.866e-11 |
4 | EXTRINSIC COMPONENT OF CYTOPLASMIC SIDE OF PLASMA MEMBRANE | 12 | 98 | 1.398e-11 | 2.041e-09 |
5 | EXTRINSIC COMPONENT OF PLASMA MEMBRANE | 13 | 136 | 4.664e-11 | 5.448e-09 |
6 | INTRINSIC COMPONENT OF THE CYTOPLASMIC SIDE OF THE PLASMA MEMBRANE | 6 | 15 | 9.289e-10 | 9.041e-08 |
7 | MEMBRANE REGION | 30 | 1134 | 2.816e-09 | 2.35e-07 |
8 | CELL JUNCTION | 30 | 1151 | 3.973e-09 | 2.721e-07 |
9 | HETEROTRIMERIC G PROTEIN COMPLEX | 7 | 32 | 4.193e-09 | 2.721e-07 |
10 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 6 | 20 | 6.967e-09 | 4.069e-07 |
11 | INTRACELLULAR VESICLE | 31 | 1259 | 7.982e-09 | 4.238e-07 |
12 | CELL SUBSTRATE JUNCTION | 17 | 398 | 1.362e-08 | 6.5e-07 |
13 | CELL LEADING EDGE | 16 | 350 | 1.447e-08 | 6.5e-07 |
14 | INTRINSIC COMPONENT OF PLASMA MEMBRANE | 35 | 1649 | 3.198e-08 | 1.334e-06 |
15 | PLASMA MEMBRANE REGION | 25 | 929 | 5.149e-08 | 2.005e-06 |
16 | CELL PROJECTION | 35 | 1786 | 2.264e-07 | 8.264e-06 |
17 | ANCHORING JUNCTION | 17 | 489 | 2.64e-07 | 9.069e-06 |
18 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 12 | 237 | 3.383e-07 | 1.098e-05 |
19 | VACUOLE | 27 | 1180 | 3.736e-07 | 1.12e-05 |
20 | MEMBRANE MICRODOMAIN | 13 | 288 | 4.026e-07 | 1.12e-05 |
21 | RUFFLE | 10 | 156 | 3.888e-07 | 1.12e-05 |
22 | PLASMA MEMBRANE PROTEIN COMPLEX | 17 | 510 | 4.751e-07 | 1.261e-05 |
23 | MEMBRANE PROTEIN COMPLEX | 24 | 1020 | 1.115e-06 | 2.713e-05 |
24 | CELL PROJECTION PART | 23 | 946 | 1.1e-06 | 2.713e-05 |
25 | CELL SURFACE | 20 | 757 | 1.698e-06 | 3.968e-05 |
26 | PERINUCLEAR REGION OF CYTOPLASM | 18 | 642 | 2.566e-06 | 5.763e-05 |
27 | ENDOSOME | 19 | 793 | 1.268e-05 | 0.0002743 |
28 | NEURON PART | 25 | 1265 | 1.411e-05 | 0.0002942 |
29 | VESICLE LUMEN | 7 | 106 | 1.88e-05 | 0.0003786 |
30 | RUFFLE MEMBRANE | 6 | 80 | 3.683e-05 | 0.000717 |
31 | NEURONAL POSTSYNAPTIC DENSITY | 5 | 53 | 5.571e-05 | 0.001037 |
32 | EXTRACELLULAR SPACE | 25 | 1376 | 5.681e-05 | 0.001037 |
33 | PLATELET ALPHA GRANULE LUMEN | 5 | 55 | 6.67e-05 | 0.00118 |
34 | PROTEIN KINASE COMPLEX | 6 | 90 | 7.161e-05 | 0.001201 |
35 | IKAPPAB KINASE COMPLEX | 3 | 11 | 7.197e-05 | 0.001201 |
36 | SYNAPSE | 17 | 754 | 7.925e-05 | 0.001286 |
37 | LEADING EDGE MEMBRANE | 7 | 134 | 8.454e-05 | 0.001334 |
38 | EARLY ENDOSOME | 10 | 301 | 0.0001234 | 0.001897 |
39 | CATALYTIC COMPLEX | 20 | 1038 | 0.0001566 | 0.002345 |
40 | SITE OF POLARIZED GROWTH | 7 | 149 | 0.000164 | 0.002394 |
41 | ACTIN FILAMENT | 5 | 70 | 0.0002114 | 0.003011 |
42 | RECEPTOR COMPLEX | 10 | 327 | 0.0002411 | 0.003352 |
43 | SECRETORY VESICLE | 12 | 461 | 0.0002586 | 0.003512 |
44 | PLATELET ALPHA GRANULE | 5 | 75 | 0.0002922 | 0.003879 |
45 | GOLGI APPARATUS | 24 | 1445 | 0.0003152 | 0.00409 |
46 | NEURON PROJECTION | 18 | 942 | 0.0003765 | 0.004779 |
47 | LAMELLIPODIUM | 7 | 172 | 0.0003939 | 0.004894 |
48 | CYTOPLASMIC REGION | 9 | 287 | 0.000412 | 0.005013 |
49 | SECRETORY GRANULE LUMEN | 5 | 85 | 0.000522 | 0.005957 |
50 | CELL PROJECTION MEMBRANE | 9 | 298 | 0.0005405 | 0.005957 |
51 | CELL CORTEX | 8 | 238 | 0.0005485 | 0.005957 |
52 | SOMATODENDRITIC COMPARTMENT | 14 | 650 | 0.0005465 | 0.005957 |
53 | MAST CELL GRANULE | 3 | 21 | 0.000548 | 0.005957 |
54 | PLASMA MEMBRANE RAFT | 5 | 86 | 0.0005508 | 0.005957 |
55 | CYTOPLASMIC VESICLE PART | 13 | 601 | 0.0008306 | 0.008819 |
56 | EXCITATORY SYNAPSE | 7 | 197 | 0.0008814 | 0.009037 |
57 | ENDOCYTIC VESICLE | 8 | 256 | 0.0008821 | 0.009037 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04014_Ras_signaling_pathway | 155 | 236 | 0 | 0 | |
2 | hsa04151_PI3K_AKT_signaling_pathway | 79 | 351 | 1.722e-98 | 1.55e-96 | |
3 | hsa04010_MAPK_signaling_pathway | 61 | 268 | 1.241e-74 | 7.443e-73 | |
4 | hsa04722_Neurotrophin_signaling_pathway | 40 | 127 | 1.659e-54 | 7.467e-53 | |
5 | hsa04510_Focal_adhesion | 45 | 200 | 5.346e-54 | 1.925e-52 | |
6 | hsa04012_ErbB_signaling_pathway | 35 | 87 | 4.001e-52 | 1.2e-50 | |
7 | hsa04810_Regulation_of_actin_cytoskeleton | 44 | 214 | 7.139e-51 | 1.836e-49 | |
8 | hsa04062_Chemokine_signaling_pathway | 40 | 189 | 1.093e-46 | 2.459e-45 | |
9 | hsa04664_Fc_epsilon_RI_signaling_pathway | 29 | 79 | 9.4e-42 | 1.88e-40 | |
10 | hsa04370_VEGF_signaling_pathway | 26 | 76 | 1.64e-36 | 2.953e-35 | |
11 | hsa04662_B_cell_receptor_signaling_pathway | 25 | 75 | 8.606e-35 | 1.408e-33 | |
12 | hsa04910_Insulin_signaling_pathway | 28 | 138 | 4.372e-32 | 6.559e-31 | |
13 | hsa04660_T_cell_receptor_signaling_pathway | 26 | 108 | 6.035e-32 | 8.357e-31 | |
14 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 24 | 95 | 4.269e-30 | 5.488e-29 | |
15 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 26 | 136 | 4.187e-29 | 5.025e-28 | |
16 | hsa04912_GnRH_signaling_pathway | 23 | 101 | 1.014e-27 | 1.14e-26 | |
17 | hsa04380_Osteoclast_differentiation | 22 | 128 | 1.179e-23 | 1.249e-22 | |
18 | hsa04914_Progesterone.mediated_oocyte_maturation | 19 | 87 | 1.131e-22 | 1.131e-21 | |
19 | hsa04620_Toll.like_receptor_signaling_pathway | 18 | 102 | 9.619e-20 | 9.113e-19 | |
20 | hsa04720_Long.term_potentiation | 16 | 70 | 1.33e-19 | 1.197e-18 | |
21 | hsa04210_Apoptosis | 17 | 89 | 2.515e-19 | 2.156e-18 | |
22 | hsa04540_Gap_junction | 17 | 90 | 3.081e-19 | 2.52e-18 | |
23 | hsa04360_Axon_guidance | 19 | 130 | 3.691e-19 | 2.889e-18 | |
24 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 13 | 42 | 4.586e-18 | 3.439e-17 | |
25 | hsa04070_Phosphatidylinositol_signaling_system | 15 | 78 | 3.147e-17 | 2.266e-16 | |
26 | hsa04670_Leukocyte_transendothelial_migration | 17 | 117 | 3.303e-17 | 2.287e-16 | |
27 | hsa04150_mTOR_signaling_pathway | 13 | 52 | 1.068e-16 | 7.12e-16 | |
28 | hsa04916_Melanogenesis | 15 | 101 | 1.842e-15 | 1.184e-14 | |
29 | hsa04730_Long.term_depression | 13 | 70 | 7.086e-15 | 4.398e-14 | |
30 | hsa04270_Vascular_smooth_muscle_contraction | 15 | 116 | 1.543e-14 | 9.259e-14 | |
31 | hsa04020_Calcium_signaling_pathway | 17 | 177 | 3.89e-14 | 2.259e-13 | |
32 | hsa04144_Endocytosis | 16 | 203 | 4.838e-12 | 2.721e-11 | |
33 | hsa04320_Dorso.ventral_axis_formation | 8 | 25 | 1.049e-11 | 5.724e-11 | |
34 | hsa04973_Carbohydrate_digestion_and_absorption | 9 | 44 | 4.489e-11 | 2.376e-10 | |
35 | hsa04920_Adipocytokine_signaling_pathway | 10 | 68 | 1.154e-10 | 5.934e-10 | |
36 | hsa04520_Adherens_junction | 10 | 73 | 2.386e-10 | 1.193e-09 | |
37 | hsa04310_Wnt_signaling_pathway | 12 | 151 | 2.269e-09 | 1.104e-08 | |
38 | hsa04630_Jak.STAT_signaling_pathway | 12 | 155 | 3.06e-09 | 1.449e-08 | |
39 | hsa04530_Tight_junction | 11 | 133 | 7.104e-09 | 3.279e-08 | |
40 | hsa04621_NOD.like_receptor_signaling_pathway | 8 | 59 | 1.722e-08 | 7.749e-08 | |
41 | hsa04972_Pancreatic_secretion | 9 | 101 | 9.085e-08 | 3.989e-07 | |
42 | hsa04971_Gastric_acid_secretion | 8 | 74 | 1.061e-07 | 4.547e-07 | |
43 | hsa04114_Oocyte_meiosis | 9 | 114 | 2.589e-07 | 1.084e-06 | |
44 | hsa04970_Salivary_secretion | 8 | 89 | 4.507e-07 | 1.844e-06 | |
45 | hsa04622_RIG.I.like_receptor_signaling_pathway | 7 | 71 | 1.287e-06 | 5.146e-06 | |
46 | hsa00562_Inositol_phosphate_metabolism | 6 | 57 | 5.15e-06 | 2.015e-05 | |
47 | hsa00565_Ether_lipid_metabolism | 5 | 36 | 8.138e-06 | 3.117e-05 | |
48 | hsa04744_Phototransduction | 4 | 29 | 7.087e-05 | 0.0002658 | |
49 | hsa04962_Vasopressin.regulated_water_reabsorption | 4 | 44 | 0.0003701 | 0.00136 | |
50 | hsa00564_Glycerophospholipid_metabolism | 5 | 80 | 0.0003946 | 0.001421 | |
51 | hsa00592_alpha.Linolenic_acid_metabolism | 3 | 20 | 0.0004724 | 0.001667 | |
52 | hsa04623_Cytosolic_DNA.sensing_pathway | 4 | 56 | 0.0009318 | 0.003225 | |
53 | hsa00591_Linoleic_acid_metabolism | 3 | 30 | 0.00159 | 0.005399 | |
54 | hsa04640_Hematopoietic_cell_lineage | 4 | 88 | 0.004888 | 0.01629 | |
55 | hsa04975_Fat_digestion_and_absorption | 3 | 46 | 0.00543 | 0.01777 | |
56 | hsa00590_Arachidonic_acid_metabolism | 3 | 59 | 0.01081 | 0.03475 | |
57 | hsa04742_Taste_transduction | 2 | 52 | 0.06152 | 0.1943 | |
58 | hsa04340_Hedgehog_signaling_pathway | 2 | 56 | 0.07004 | 0.2174 | |
59 | hsa04976_Bile_secretion | 2 | 71 | 0.105 | 0.3203 | |
60 | hsa04145_Phagosome | 3 | 156 | 0.1211 | 0.3633 | |
61 | hsa04350_TGF.beta_signaling_pathway | 2 | 85 | 0.1409 | 0.4123 | |
62 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 3 | 168 | 0.142 | 0.4123 | |
63 | hsa04740_Olfactory_transduction | 5 | 388 | 0.1836 | 0.5246 | |
64 | hsa04390_Hippo_signaling_pathway | 2 | 154 | 0.3356 | 0.9437 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | PCA3 |
hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7f-1-3p;hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-1-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-20a-5p;hsa-miR-27a-3p;hsa-miR-320b;hsa-miR-33a-3p;hsa-miR-3662;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-616-5p;hsa-miR-944 | 20 | FGF7 | Sponge network | -2.778 | 8.0E-5 | -1.56 | 0.00499 | 0.493 |
2 | RFPL1S |
hsa-miR-106b-5p;hsa-miR-107;hsa-miR-17-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-320b;hsa-miR-33a-3p;hsa-miR-362-3p;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-505-3p | 11 | AKT3 | Sponge network | -0.223 | 0.70704 | -0.749 | 0.06936 | 0.466 |
3 | MEG3 |
hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-1-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-20a-5p;hsa-miR-31-5p;hsa-miR-320b;hsa-miR-33a-3p;hsa-miR-3662;hsa-miR-429;hsa-miR-577;hsa-miR-616-5p;hsa-miR-7-1-3p | 16 | FGF7 | Sponge network | -1.645 | 0.00049 | -1.56 | 0.00499 | 0.458 |
4 | PCA3 |
hsa-miR-1254;hsa-miR-1271-5p;hsa-miR-141-3p;hsa-miR-17-3p;hsa-miR-182-5p;hsa-miR-185-3p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-193b-5p;hsa-miR-200a-3p;hsa-miR-22-5p;hsa-miR-224-5p;hsa-miR-23a-3p;hsa-miR-590-3p;hsa-miR-616-5p;hsa-miR-671-5p;hsa-miR-939-5p;hsa-miR-940;hsa-miR-96-5p | 19 | GNG7 | Sponge network | -2.778 | 8.0E-5 | -3.457 | 0 | 0.457 |
5 | PCA3 |
hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7f-1-3p;hsa-miR-128-3p;hsa-miR-130b-3p;hsa-miR-193b-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-301a-3p;hsa-miR-335-5p;hsa-miR-590-3p;hsa-miR-671-5p | 15 | KIT | Sponge network | -2.778 | 8.0E-5 | -3.335 | 0 | 0.45 |
6 | MEG3 |
hsa-miR-130b-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-182-5p;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-429;hsa-miR-652-3p;hsa-miR-7-1-3p;hsa-miR-96-5p | 11 | MRAS | Sponge network | -1.645 | 0.00049 | -0.939 | 0.01023 | 0.445 |
7 | CASC2 | hsa-miR-183-5p;hsa-miR-193b-3p;hsa-miR-193b-5p;hsa-miR-218-5p;hsa-miR-22-5p;hsa-miR-224-5p;hsa-miR-2355-3p;hsa-miR-24-2-5p;hsa-miR-369-3p;hsa-miR-452-5p;hsa-miR-654-3p;hsa-miR-944 | 12 | PRKCA | Sponge network | -0.561 | 0.05962 | -0.525 | 0.15685 | 0.436 |
8 | MEG3 |
hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-320b;hsa-miR-33a-3p;hsa-miR-3662;hsa-miR-577;hsa-miR-592;hsa-miR-629-5p | 13 | IGF1 | Sponge network | -1.645 | 0.00049 | -2.083 | 0.00135 | 0.434 |
9 | PCA3 |
hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7f-1-3p;hsa-miR-103a-3p;hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-1-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-186-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-330-3p;hsa-miR-335-5p;hsa-miR-3662;hsa-miR-3682-3p;hsa-miR-424-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-93-3p | 28 | FGF2 | Sponge network | -2.778 | 8.0E-5 | -1.879 | 0.00013 | 0.416 |
10 | MEG3 |
hsa-miR-103a-3p;hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-1-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-330-3p;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-3662;hsa-miR-429;hsa-miR-577;hsa-miR-93-3p | 19 | FGF2 | Sponge network | -1.645 | 0.00049 | -1.879 | 0.00013 | 0.415 |
11 | MEG3 |
hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-330-3p;hsa-miR-335-3p;hsa-miR-577 | 11 | FGFR1 | Sponge network | -1.645 | 0.00049 | -1.499 | 0.00051 | 0.412 |
12 | PCA3 |
hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-181b-5p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-301a-3p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-33a-3p;hsa-miR-3662;hsa-miR-454-3p;hsa-miR-576-5p;hsa-miR-590-3p;hsa-miR-629-5p;hsa-miR-940 | 24 | IGF1 | Sponge network | -2.778 | 8.0E-5 | -2.083 | 0.00135 | 0.404 |
13 | PCA3 |
hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7f-1-3p;hsa-miR-107;hsa-miR-1254;hsa-miR-130b-5p;hsa-miR-148b-5p;hsa-miR-15b-3p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-224-5p;hsa-miR-23a-3p;hsa-miR-25-3p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-33a-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-5p | 19 | GRIN2A | Sponge network | -2.778 | 8.0E-5 | -3.62 | 0 | 0.401 |
14 | EMX2OS |
hsa-miR-107;hsa-miR-1254;hsa-miR-130b-5p;hsa-miR-15b-3p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-32-3p;hsa-miR-335-3p;hsa-miR-577;hsa-miR-877-5p;hsa-miR-92a-3p | 11 | GRIN2A | Sponge network | -1.088 | 0.10042 | -3.62 | 0 | 0.393 |
15 | PCA3 |
hsa-miR-141-5p;hsa-miR-16-2-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-23a-3p;hsa-miR-24-3p;hsa-miR-27a-3p;hsa-miR-452-3p;hsa-miR-589-3p;hsa-miR-589-5p;hsa-miR-590-5p;hsa-miR-616-5p | 12 | PRKCB | Sponge network | -2.778 | 8.0E-5 | -1.403 | 0.00367 | 0.387 |
16 | DGCR5 |
hsa-miR-107;hsa-miR-140-3p;hsa-miR-148a-5p;hsa-miR-30d-3p;hsa-miR-30d-5p;hsa-miR-326;hsa-miR-338-3p;hsa-miR-362-5p;hsa-miR-501-5p;hsa-miR-577 | 10 | NTRK2 | Sponge network | 1.383 | 0.01835 | 0.129 | 0.90432 | 0.38 |
17 | MEG3 |
hsa-let-7g-3p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-196a-5p;hsa-miR-196b-5p;hsa-miR-20a-5p;hsa-miR-219a-5p;hsa-miR-335-3p;hsa-miR-93-5p;hsa-miR-96-5p | 14 | PDGFRA | Sponge network | -1.645 | 0.00049 | -1.161 | 0.00469 | 0.38 |
18 | DGCR5 |
hsa-let-7g-5p;hsa-miR-140-3p;hsa-miR-148a-5p;hsa-miR-150-5p;hsa-miR-192-5p;hsa-miR-194-3p;hsa-miR-194-5p;hsa-miR-215-5p;hsa-miR-30d-5p;hsa-miR-362-3p;hsa-miR-375;hsa-miR-500a-3p;hsa-miR-577;hsa-miR-592;hsa-miR-625-5p;hsa-miR-7-5p | 16 | IGF1R | Sponge network | 1.383 | 0.01835 | -0.553 | 0.17433 | 0.365 |
19 | EMX2OS |
hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-192-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-3p;hsa-miR-215-5p;hsa-miR-222-3p;hsa-miR-29a-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-503-5p;hsa-miR-577;hsa-miR-589-3p;hsa-miR-92a-3p;hsa-miR-93-3p | 22 | FGF2 | Sponge network | -1.088 | 0.10042 | -1.879 | 0.00013 | 0.362 |
20 | EMX2OS |
hsa-miR-107;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-32-3p;hsa-miR-335-3p;hsa-miR-362-3p;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-505-3p;hsa-miR-577 | 12 | AKT3 | Sponge network | -1.088 | 0.10042 | -0.749 | 0.06936 | 0.354 |
21 | PCA3 |
hsa-let-7b-5p;hsa-let-7d-5p;hsa-miR-1301-3p;hsa-miR-130b-5p;hsa-miR-134-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-185-3p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-2355-3p;hsa-miR-296-5p;hsa-miR-452-3p;hsa-miR-589-3p;hsa-miR-629-3p;hsa-miR-93-3p;hsa-miR-940 | 17 | GAB2 | Sponge network | -2.778 | 8.0E-5 | -1.242 | 0.00013 | 0.342 |
22 | HAR1A | hsa-miR-1254;hsa-miR-141-3p;hsa-miR-17-3p;hsa-miR-182-5p;hsa-miR-185-3p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-193b-5p;hsa-miR-224-5p;hsa-miR-671-5p;hsa-miR-940 | 11 | GNG7 | Sponge network | -0.801 | 0.17598 | -3.457 | 0 | 0.341 |
23 | EMX2OS |
hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-20a-5p;hsa-miR-424-5p;hsa-miR-577;hsa-miR-7-1-3p | 10 | FGF7 | Sponge network | -1.088 | 0.10042 | -1.56 | 0.00499 | 0.338 |
24 | AGAP11 |
hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-181b-5p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-320b;hsa-miR-3662;hsa-miR-421;hsa-miR-629-5p | 14 | IGF1 | Sponge network | -1.728 | 0.00016 | -2.083 | 0.00135 | 0.332 |
25 | AGAP11 |
hsa-miR-16-1-3p;hsa-miR-18a-5p;hsa-miR-222-5p;hsa-miR-26b-3p;hsa-miR-29a-5p;hsa-miR-320b;hsa-miR-326;hsa-miR-532-3p;hsa-miR-590-5p;hsa-miR-629-5p | 10 | FGF1 | Sponge network | -1.728 | 0.00016 | -0.16 | 0.73397 | 0.329 |
26 | EMX2OS |
hsa-miR-1254;hsa-miR-141-3p;hsa-miR-17-3p;hsa-miR-182-5p;hsa-miR-185-3p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-200a-3p;hsa-miR-3127-5p;hsa-miR-92a-3p | 10 | GNG7 | Sponge network | -1.088 | 0.10042 | -3.457 | 0 | 0.327 |
27 | RFPL1S |
hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-141-5p;hsa-miR-18a-5p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-29b-1-5p;hsa-miR-34a-5p;hsa-miR-429;hsa-miR-7-1-3p | 12 | GAB1 | Sponge network | -0.223 | 0.70704 | -0.958 | 0.00019 | 0.32 |
28 | RFPL1S |
hsa-miR-107;hsa-miR-192-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-215-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-29a-5p;hsa-miR-335-5p;hsa-miR-429 | 12 | FGF2 | Sponge network | -0.223 | 0.70704 | -1.879 | 0.00013 | 0.314 |
29 | MEG3 |
hsa-miR-106b-5p;hsa-miR-107;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-320b;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-577;hsa-miR-616-5p | 11 | AKT3 | Sponge network | -1.645 | 0.00049 | -0.749 | 0.06936 | 0.312 |
30 | PCA3 |
hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-let-7f-1-3p;hsa-let-7g-3p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-149-5p;hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-196a-5p;hsa-miR-196b-5p;hsa-miR-20a-5p;hsa-miR-219a-5p;hsa-miR-224-5p;hsa-miR-24-3p;hsa-miR-27a-3p;hsa-miR-301a-3p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-590-5p;hsa-miR-93-5p;hsa-miR-944;hsa-miR-96-5p | 26 | PDGFRA | Sponge network | -2.778 | 8.0E-5 | -1.161 | 0.00469 | 0.31 |
31 | PCA3 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-128-3p;hsa-miR-144-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-324-3p;hsa-miR-330-3p;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-96-5p | 28 | PIK3R1 | Sponge network | -2.778 | 8.0E-5 | -1.094 | 2.0E-5 | 0.309 |
32 | NEAT1 | hsa-let-7b-5p;hsa-let-7d-5p;hsa-miR-1301-3p;hsa-miR-130b-5p;hsa-miR-134-5p;hsa-miR-181b-5p;hsa-miR-185-3p;hsa-miR-296-5p;hsa-miR-452-3p;hsa-miR-629-3p;hsa-miR-93-3p;hsa-miR-940 | 12 | GAB2 | Sponge network | -0.686 | 0.02293 | -1.242 | 0.00013 | 0.302 |
33 | RFPL1S |
hsa-miR-126-5p;hsa-miR-18a-5p;hsa-miR-222-5p;hsa-miR-26b-3p;hsa-miR-29a-5p;hsa-miR-320b;hsa-miR-330-5p;hsa-miR-429;hsa-miR-532-3p;hsa-miR-550a-5p;hsa-miR-625-5p;hsa-miR-7-5p | 12 | FGF1 | Sponge network | -0.223 | 0.70704 | -0.16 | 0.73397 | 0.3 |
34 | MEG3 |
hsa-let-7d-5p;hsa-let-7g-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-128-3p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-335-5p;hsa-miR-33a-3p;hsa-miR-378a-3p;hsa-miR-429;hsa-miR-7-1-3p | 17 | ABL2 | Sponge network | -1.645 | 0.00049 | 0.257 | 0.18922 | 0.297 |
35 | RFPL1S |
hsa-miR-106b-5p;hsa-miR-107;hsa-miR-126-5p;hsa-miR-1266-5p;hsa-miR-148a-5p;hsa-miR-17-3p;hsa-miR-188-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-26b-5p;hsa-miR-29a-3p;hsa-miR-30d-3p;hsa-miR-335-5p;hsa-miR-33a-3p;hsa-miR-378a-3p;hsa-miR-378c;hsa-miR-429;hsa-miR-7-1-3p | 20 | ABL2 | Sponge network | -0.223 | 0.70704 | 0.257 | 0.18922 | 0.29 |
36 | AGAP11 |
hsa-let-7f-1-3p;hsa-miR-107;hsa-miR-130b-5p;hsa-miR-148b-5p;hsa-miR-15b-3p;hsa-miR-25-3p;hsa-miR-320b;hsa-miR-335-3p;hsa-miR-590-5p;hsa-miR-629-5p | 10 | GRIN2A | Sponge network | -1.728 | 0.00016 | -3.62 | 0 | 0.283 |
37 | EMX2OS |
hsa-miR-135b-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-335-3p;hsa-miR-577 | 10 | FGFR1 | Sponge network | -1.088 | 0.10042 | -1.499 | 0.00051 | 0.281 |
38 | EMX2OS |
hsa-miR-15a-5p;hsa-miR-192-5p;hsa-miR-194-3p;hsa-miR-194-5p;hsa-miR-196a-5p;hsa-miR-215-5p;hsa-miR-335-3p;hsa-miR-34a-5p;hsa-miR-362-3p;hsa-miR-500a-3p;hsa-miR-577;hsa-miR-592;hsa-miR-625-5p;hsa-miR-7-1-3p;hsa-miR-7-5p;hsa-miR-877-5p | 16 | IGF1R | Sponge network | -1.088 | 0.10042 | -0.553 | 0.17433 | 0.28 |
39 | PCA3 |
hsa-miR-183-5p;hsa-miR-193b-3p;hsa-miR-193b-5p;hsa-miR-200c-3p;hsa-miR-22-5p;hsa-miR-224-5p;hsa-miR-2355-3p;hsa-miR-369-3p;hsa-miR-590-3p;hsa-miR-93-3p;hsa-miR-944 | 11 | PRKCA | Sponge network | -2.778 | 8.0E-5 | -0.525 | 0.15685 | 0.278 |
40 | PCA3 |
hsa-miR-130b-5p;hsa-miR-135b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-96-5p | 10 | RGL1 | Sponge network | -2.778 | 8.0E-5 | -0.192 | 0.50814 | 0.274 |
41 | AGAP11 |
hsa-let-7f-1-3p;hsa-miR-106b-5p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-18a-5p;hsa-miR-20a-5p;hsa-miR-212-3p;hsa-miR-29b-1-5p;hsa-miR-335-3p;hsa-miR-93-5p | 11 | GAB1 | Sponge network | -1.728 | 0.00016 | -0.958 | 0.00019 | 0.269 |
42 | PCA3 |
hsa-miR-1180-3p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-141-5p;hsa-miR-193b-3p;hsa-miR-200c-3p;hsa-miR-23a-3p;hsa-miR-27b-5p;hsa-miR-769-5p;hsa-miR-940 | 10 | ETS1 | Sponge network | -2.778 | 8.0E-5 | 0.008 | 0.97952 | 0.268 |
43 | DGCR5 |
hsa-let-7g-5p;hsa-miR-107;hsa-miR-126-5p;hsa-miR-1266-5p;hsa-miR-140-3p;hsa-miR-148a-5p;hsa-miR-188-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-30d-3p;hsa-miR-30d-5p | 14 | ABL2 | Sponge network | 1.383 | 0.01835 | 0.257 | 0.18922 | 0.26 |
44 | EMX2OS |
hsa-let-7g-3p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-196a-5p;hsa-miR-196b-5p;hsa-miR-20a-5p;hsa-miR-335-3p;hsa-miR-33b-5p | 10 | PDGFRA | Sponge network | -1.088 | 0.10042 | -1.161 | 0.00469 | 0.259 |
45 | PCA3 |
hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-320b;hsa-miR-330-3p;hsa-miR-335-5p;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-590-5p | 10 | SOS2 | Sponge network | -2.778 | 8.0E-5 | -0.553 | 0.00084 | 0.258 |
46 | PCA3 |
hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-200c-3p;hsa-miR-330-3p;hsa-miR-590-5p;hsa-miR-93-5p;hsa-miR-96-5p | 11 | PRKACB | Sponge network | -2.778 | 8.0E-5 | -2.003 | 0 | 0.257 |